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ABSTRACT 
______________________________________________________ 
 
Many abnormalities of the placenta are reported to be significant in the setting of maternal 
health problems and adverse fetal/neonatal outcomes. In specific clinicopathological 
circumstances - eg vascular lesions in the growth restricted fetus – correlation does exist 
between the placental lesion and the clinical event. Relationships between “lower grade” 
placental lesions and clinical outcomes are less clear. Reports of associations between 
selected abnormalities and clinical outcomes are largely based on retrospective case 
control studies: the clinical groups studied tend to be high-risk. Understanding of the 
significance of these lesions in the wider population is lacking. 
 
This study reports on the clinical events and placental lesions documented in 1119 
unselected women delivering at the conclusion of a singleton pregnancy in a single 
obstetric centre. Study methodology was such that the cohort comprised low-risk mothers 
delivering at or close to term.  
 
The incidence of potentially adverse obstetric and neonatal events in the study population 
was low. 97% delivered at term. Mean birth weight was 3485 g; mean Apgar scores were 9 
at 1 minute and 10 at 5 minutes. 5.9% of infants required admission to neonatal intensive 
care. When classified in accordance with current standard reporting guidelines, 71% of 
placentas were classified as normal. Inclusion of lower grade histological lesions in the 
reporting schedule reduced the percentage of histologically normal placentas to 58%. 
Funisitis was found to be significantly correlated with adverse neonatal outcome. A 
number of other placental lesions - including cord coiling <10th and >90th centiles, 
placental infarction, villitis of unknown etiology and lower grades of acute placental 
inflammation - were not found to be associated with adverse obstetric or neonatal events. It 
is concluded that a number of placental lesions may not be relevant to adverse pregnancy 
outcomes in a low-risk population.
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CHAPTER ONE: INTRODUCTION 
______________________________________________________ 
 
 
Summary: 
 
 Brief background with justification of study 
 Aims and objectives  
 Normal placenta  
o Normal placental development  
o Macroscopic examination of the placenta  
o Normal macroscopic appearance 
o Normal histology of third trimester placenta 
 Definitions of key placental lesions 
o Macroscopic 
o Histological 
 Definitions of adverse clinical events 
 Current evidence supporting association of adverse clinical events and 
key placental lesions 
 
 
 
 
 
 
 
 
 
 
 
 
 
      
 Page |  2 
1.1 BACKGROUND 
 
Since the 19
th
 century, a fundamental concept of histopathology has been the correlation of 
reproducibly recognizable abnormal morphological patterns with specific disease 
processes: Rokitansky’s and Aschoff’s realization that identifiable macroscopic 
abnormalities seen at post-mortem examination mapped to an individual disease noted in 
the patient before death (1) was subsequently developed by Rudolf Virchow, who linked 
histologically recognizable patterns of cell injury with specific disease processes (2). In 
modern clinicopathological practice, a specific disease may be considered to be understood 
fully when the aetiology (cause) and pathogenesis (mechanisms of development) are 
defined, a morphological pattern recognized and a clinical consequence understood.  
 
For a large number of human diseases, this four step pathway is at least partially complete. 
As a minimum, in the day to day clinical practice of modern histopathology, the definition 
and recognition of a morphological pattern must be sufficiently secure to allow a diagnosis 
to be recorded and a clinical management plan to be instituted, even if a full understanding 
of the environmental and genetic events underlying the aetiology and pathogenesis is more 
limited. 
 
The process of disease recognition begun by Virchow’s microscopic observations of 
human tissues many decades ago is, for the placenta, fragmented and lacking in evidence. 
There exist large numbers of publications concerning a wide spectrum of histological 
abnormalities of the placenta, but study design is often limited to case series, case control 
or retrospective cohort analysis. Clinical and histological definitions of specific disease 
processes in many placental studies are extremely variable (3, 4). Also important, if 
difficult to quantify, is the effect of progress in medical care. Clinical outcomes are based 
not only on maternal clinical disease or placental pathology (well characterised or 
otherwise) but are also highly dependent on clinical care received during the progress of 
the pregnancy.  Historical differences in clinical outcomes between older and more recent 
studies are likely, making comparison of older and contemporary studies potentially 
unreliable.  
 
Whether the starting points for review of the literature are macroscopic/microscopic 
findings projected onto clinical outcomes or clinical outcomes reviewed retrospectively 
against placental morphology, the findings are confusing, conflicting and difficult to apply 
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to routine clinical practice. Here, current studies and hypotheses are examined, 
highlighting where appropriate conflicting evidence and uncertainties. 
1.2. AIMS AND OBJECTIVES 
 
This study, which prospectively follows, in a single centre, an unselected cohort of 1119 
subjects with an ongoing singleton pregnancy delivering at or close to term, seeks to define 
the associations of clearly defined placental lesions with specific clinical outcomes in term 
pregnancy.   
 
Normal growth and development of the placenta is reviewed, emphasizing those aspects 
which, when disrupted, are currently believed to underly subsequent histological 
abnormalities and adverse clinical outcomes. A brief overview of selected macroscopic 
findings in the term placenta (including the umbilical cord) is given. A description of 
normal term placental histology is presented, together with definitions of abnormal 
placental histological findings, the latter placed in the context of current published 
evidence for clinicopathological findings. Current concepts of mechanisms of placental 
disease are explored. Definitions of significant clinical outcomes are given. A 
comprehensive review explores the current evidence linking placental abnormality with 
adverse clinical outcome from two perspectives: prospective studies describing placental 
abnormality with clinical outcomes and retrospective studies recording placental changes 
in the setting of defined clinical events. 
 
As an initial step, all delivered placentas in this study are reported histologically within the 
framework of current normal clinical practice. To determine whether the presence of some 
rarer placental abnormalities, or the severity or extent of more specifically defined 
common placental abnormalities correlates well with clinical complications of pregnancy, 
a more extended morphological and histomorphometric analysis of placental subgroups 
within the cohort is undertaken and related to detailed clinical outcomes.  
 
The findings from the analysis of  umbilical cord coiling are placed in the relatively novel 
context  - for a histopathological study - of systematic reviewing of the relevant literature.  
The conventional systematic review construct is modified to create a model allowing 
assessment of the clinical implications of a suspected pathological change. 
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Pilot immunohistochemical studies are undertaken, with analysis of the inflammatory cell 
population in presumed non-infective placental inflammation (villitis of unknown etiology) 
and markers of apoptosis and oxidative stress injury in placental infarction .  
1.3. NORMAL PLACENTAL DEVELOPMENT AND HISTOLOGY 
 
1.3.1 Normal placental development 
Detailed descriptions of normal placental histology date from the 1950s and are based on a 
unique collection of embryos identified within hysterectomy specimens, assembled in 
Cambridge by JD Boyd and studied in collaboration with WJ Hamilton (Charing Cross 
Medical School). Descriptions of the histological appearances of these embryos, from the 
earliest days of implantation to crown-rump length (CRL) of approximately 90mm, remain 
the most comprehensive within the published literature (5, 6). Photomicrographs of 
haematoxylin and eosin stained whole mount uterine sections from the collection are 
shown in Figure 1.1. 
 
 
 
Figure 1.1: Boyd collection. Human embryo CR length 20mm and 90mm, 8.5 and 15.5 
completed gestational weeks (low power) (7, 8). 
 
In summary, placental development begins with the growth of trabecular columns formed 
by primitive syncytium, partially surrounding lacunar spaces.  These columns become 
radially arranged and are subsequently invaded by cytotrophoblast.  Secondary villi then 
develop.  Spiral arteries within the myometrium do not open directly into the intervillous 
space: maternal blood flow (once established) is via gaps within the trophoblastic shell and 
drainage is via randomly distributed venous openings.  With growth and development, 
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maternal arteries communicate with the intervillous space via random perforations of the 
basal plate.  These arteries are invaded by cytotrophoblast.  Chorionic villi, as they grow, 
have an invasive phenotype and can be seen lying within uterine veins.  The placenta 
continues to grow in circumference throughout the pregnancy, at least in part by ongoing 
growth at the placental edge. 
 
Growth of the placenta in the first trimester is supported by secretions from the 
endometrial glands delivered into the placenta through the developing basal plate and 
shows little variation within the human population (9).  This form of nutrition, described as 
histiotrophic, is not dependent on maternal arterial circulation to the placenta: during the 
first trimester, maternal blood flow is prevented from entering the placental intervillous 
space by intravascular trophoblast occluding the tips of spiral arteries.  Oxygen 
concentrations within the developing chorionic sac are thus relatively low. The first 
trimester is the period within which embryonic organogenesis occurs and the developing 
organs within this environment of relatively low oxygen concentrations are believed to be 
protected from teratogenesis mediated by reactive oxygen species (ROS) (10). In order to 
meet the energy demands required for growth and development of the metabolically active 
human fetus, the placental circulation derives from the maternal arterial circulation from 
the end of the first trimester.  The subsequent threefold rise in intraplacental oxygen 
concentration permits high energy electron transfers, particularly within mitochondria, but 
also results in the increased production of potentially damaging ROS (11).  The change in 
perfusion comes about through cytotrophoblast invasion of the decidual maternal spiral 
arteries, with replacement of the smooth muscle by fibrinoid material and increased 
maternal vessel diameter (12). Further placental growth through the second and third 
trimesters is via circumferential growth, with expansion of the villous tree as primary villi 
give rise to intermediate and terminal villi (13).  
 
1.3.2 Normal histology 
 
Standard light microscopic examination of the term placenta demonstrates the 
characteristic morphology of umbilical cord, membranes, chorionic plate, chorionic villi, 
intervillous space and decidua with included maternal vessels. The normal morphology of 
these structures has been widely reviewed in standard textbooks (3, 14). 
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1.4. MACROSCOPIC APPEARANCES OF TERM PLACENTA 
 
A comprehensive review of all possible placental macroscopic findings is beyond the 
scope of this study. Standard textbooks (3, 14) were referred to throughout this study. The 
most relevant macroscopic placental findings are reviewed below. 
 
1.4.1 Normal macroscopic placental findings 
 
Placental disc 
The normal placenta at term has a round to ovoid shape, with average weight 470g, 
average diameter 22cm and average thickness 2.5cm (14). The degree of variation in 
placental shape (placental eccentricity) is reported to be high (15, 16). The fetal surface is 
smooth, with vessels radiating from the point of umbilical cord insertion. The maternal 
surface represents the plane of separation of the placenta from the uterine wall - which 
occurs physiologically at the conclusion of the second stage of labour. The basal plate – the 
deepest part of the delivered placenta, is thus composed of a fusion of the deepest 
chorionic villi and the most superficial maternal decidua. The placental bed remains in 
utero, with admixed residual invasive trophoblast. The maternal surface of the placenta 
appears grooved: this appearance is attributable to folds of the basal plate extending 
upwards within the placental parenchyma. These folds are termed placental septa. The 
intervening aggregates of chorionic villi have a lobular form and are termed cotyledons. 
The macroscopic appearances of a serially sliced, normal term placenta are shown in 
Figure 1.2. 
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Figure 1.2. Serially sliced placenta, 39 weeks gestation, unremarkable cut surface. 
 
Umbilical cord 
The umbilical cord has a spiral or coiled structure, parallel to the course of the vessels 
within. Many studies identify one twist (complete turn through 360°) per 5cm length of 
cord as approximately the median rate of spiralling – the coiling index, more formally 
defined as the number of complete coils divided by the length of the cord in cm (17). The 
macroscopic appearances of normal coiling, hyper-coiling (>90
th
 centile) and hypo-coiling 
(<10
th
 centile) of the umbilical cord are illustrated in Figures 1.3 – 1.5. Approximately 
90% of cords have a predominantly left-handed spiral or twist, with most of the remainder 
predominantly right-handed. A small proportion of cords lack any evidence of coiling at all 
- so-called “flat cords” (18).  
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Figure 1.3. Normally coiled umbilical cord, 39 weeks gestation. 
 
Figure 1.4. Hyper-coiled umbilical cord, 38 weeks gestation. 
 
Figure 1.5. Hypo-coiled umbilical cord, 39 weeks gestation. 
 
 
 
1.4.2 Macroscopic appearances of placental infarcts 
 
Placental infarcts are variable in size, shape and distribution, but most commonly are seen 
as pale, roughly wedge-shaped lesions with the base lying just above the basal plate. Size 
ranges from a few millimetres to a centimetre or more, and location is most often 
peripheral, but may be located anywhere within the parenchyma (3). Recognition of 
infarcts relies on their increased density to palpation as well as their macroscopic 
appearance, which ranges from a dense dark red fresh lesion progressively to 
brown/yellow/white (3); although the appearances are quite characteristic, some 
commentators note the possibility of overlap of macroscopic features between infarcts and 
intervillous thrombi (qv) (19). The typical macroscopic appearances of placental infarction 
are illustrated in Figure 1.6. The incidence of macroscopic infarction reported in the 
literature is variable, but has been stated to fall into a range of 10-25% of delivered 
placentas (20). This has been questioned in a smaller study, which found a rate of 3% (4 
/126 cases) in uncomplicated pregnancies at term (21). 
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Figure 1.6. Serially sliced placenta, 39 weeks gestation, showing infarcts of varying age 
(arrows). 
 
1.4.3 Macroscopic appearances of intervillous thrombi 
 
Intervillous thrombi form a subset of all placental thrombi/haematomas, but are the most 
common thrombotic lesion, with an incidence of 14% in one study (19). Their macroscopic 
appearances are those of laminated thrombi, often multiple and distributed throughout the 
placental parenchyma (3).  
 
1.4.4 Macroscopic appearances of fetal thrombotic vasculopathy 
 
These lesions are characterized by a wedge of pale chorionic villi (22, 23), usually with the 
base of the wedge abutting the basal plate. It is said that the lesions are difficult to identify 
in the unfixed placenta, being much more apparent as an area of pallor following fixation 
(3). 
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1.5. MACROSCOPIC AND MICROSCOPIC FINDINGS IN TERM PLACENTA; 
CURRENT EVIDENCE FOR CORRELATION WITH ADVERSE CLINICAL 
OUTCOME 
 
1.5.1 Variations in placental shape and cord insertion centrality 
 
The clinical significance of placental shape variation is controversial. Increasing the 
deviation from true circularity has been reported in one prospective cohort to be associated 
with decreased placental efficiency (16), but similar assessment of shape variation was not 
found to be associated with a range of common obstetric outcomes (24). Variations in cord 
insertion site centrality are also of uncertain clinical significance, with suggestions of 
reduced placental insufficiency (24, 25) balanced against no demonstrable association with 
common obstetric outcomes (24). Velamentous cord insertion has also been associated 
with placental insufficiency (26). 
 
1.5.2 Placental infarction 
Placental infarction is recurrently reported to be associated with fetal growth restriction, 
both early and late onset. The majority of studies report outcomes in pre-term infants (27-
32). Placental infarction has also been suggested as a possible risk factor for cerebral palsy 
in one study (33). Placental infarction at term is less commonly reported, but is also 
reported to be associated with fetal growth restriction (34) and some adverse maternal 
obstetric characteristics (20).   
 
1.5.3 Chorioamnionitis and funisitis 
Chorioamnionitis is defined as acute inflammation (polymorph mediated) of the placental 
membranes, while funisitis is infiltration of the umbilical cord tissues by a polymorph 
population. The histological diagnosis relies on routine haematoxylin and eosin staining of 
paraffin sections of membranes and cord, establishing the presence or absence of an acute 
inflammatory cell (predominantly neutrophil leucocyte) infiltrate in these tissues.   
 
Migration of acute inflammatory cells in chorioamnionitis and funisitis follows a 
sequential pattern. The extra-placental membranes are first involved, followed by 
infiltration of the subchorionic fibrin, ie just below the chorionic plate.  There is then 
extension of the infiltrate from subchorionic fibrin into the chorionic plate.  The fetal 
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vessels within the chorionic plate subsequently become infiltrated by polymorphs and, 
lastly, the umbilical cord becomes involved: acute inflammatory cells infiltrate umbilical 
vessel walls and then extend into Wharton’s jelly. 
 
 
Figure 1.7. Photomicrograph of placental membranes (left) and umbilical cord (right) 
showing infiltrate of polymorphonuclear leukocytes, 40 weeks gestation (x 10 objective). 
 
A number of studies, relying on the interpretation of fluorescence in situ hybridization 
studies of the X and Y chromosomes in male infants, have been carried out, to determine 
the origin of the inflammatory response in each micro-anatomical compartment.  These 
demonstrate that maternal polymorphonuclear leukocytes form the predominant group of 
inflammatory cells in the extra-placental membranes and subchorionic fibrin, while fetal 
polymorphonuclear leukocytes form the predominant group in the infiltrate within the 
umbilical cord and chorionic plate (35). This demonstration may, in practical terms, be 
relied on to support differentiation of maternal from fetal inflammatory response in H&E-
stained sections. Figure 1.7 shows the histological features of inflamed membranes 
(maternal inflammatory response) and inflamed umbilical cord (fetal inflammatory 
response). 
Histological assessment of membranes and cord has been subject to a number of grading 
systems, mostly in research settings. The most commonly cited system (36) of identifying 
various reaction patterns of inflammation describes both maternal and fetal inflammatory 
response in terms of stage and grade, with stage corresponding to degree of progression of 
inflammation and grade relating to the intensity of the infiltrate. Stage is subdivided into 
three groups (early, intermediate and advanced) and grade into two (mild-moderate and 
severe). It should be noted that, for the twenty cases which formed the basis of this 
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classification, overall interobserver agreement stood at 81%. In addition, while there is 
some evidence supporting the association of severe grade inflammation with clinical 
outcome, the overall clinical significance of this classification system remains untested on 
a normal population 
 
The true incidences of histological chorioamnionitis and funisitis vary according to the 
population characteristics.  Histological chorioamnionitis appears to have a definite 
relationship with gestational age, the highest frequency affecting spontaneous miscarriages 
at 20–24weeks of gestation (around 80–90% of cases), falling to around 10% of deliveries 
at term. The integrity of the placental membranes is also important: histological 
chorioamnionitis is identified in around 30% of all preterm labour with intact membranes 
but rises to 50% of those presenting with preterm premature rupture of membranes (37, 
38). Longer duration of labour is also associated with increased frequency of histological 
chorioamnionitis, being reported in 20–30% of deliveries following labour compared to 
<5% delivering at term with no labour (39, 40).   
 
1.5.4. Histological changes reported as markers of impaired perfusion 
Terminal chorionic villi may appear both small for the gestational age and widely spaced 
(with increased intervillous space): this histological lesion is said to be associated with 
impaired maternal perfusion (41). The lesion is also known as accelerated villous 
maturation or distal villous hypoplasia, descriptive terms encompassing what is 
hypothesized to be the adaptive nature of the histological appearance in the face of reduced 
perfusion. 
Maternal vasculopathy is defined as persistence of muscularisation (i.e. absence of 
physiological conversion by means of trophoblast invasion) at term, and also atherosis 
characterised by fibrin and necrosis of the arterial wall together with an intramural 
accumulation of lipid-laden macrophages and perivascular lymphocytes.  These changes 
are relatively rarely seen in the intra-decidual segment of the placental bed spiral arteries, 
being more detectable in arteries deeper within the maternal arterial bed (3). 
Chorangiosis is defined histologically as multiple (at least 3) areas within the placenta 
where 10 chorionic villi contain 10 or more vessels, in non-infarcted zones. The incidence 
in an unselected population was reported to be 5.5% (42).  
Syncytial knots are morphologically recognizable as dense aggregated nuclear material 
within syncytiotrophoblast, at the periphery of chorionic villi.  Historically, these have 
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been regarded as evidence for uteroplacental ischaemia or fetal stress, although more 
recent discussions have centred around their role in placental apoptosis (43).   
A placental infarct is a localised area of ischaemic villous necrosis.  They may be central, 
peripheral or both: most are roughly triangular, with the base adjoining the basal plate.  
Ovoid or spherical infarcts are less common.  Infarcts may be of varying age.  The 
macroscopic and microscopic appearances are variable.  Fresh infarcts are macroscopically 
red, becoming white as they mature.  Histologically, an early infarct shows aggregated villi 
with obliterated intervillous space (illustrated in Figure 1.8), maturing into an old infarct, 
composed of crowded avascular villi (3).  The incidence of placental infarcts is reported to 
be between 10 and 25% in uncomplicated pregnancy (19, 20), although may be less in the 
setting of more modern obstetric care (21).  The instance is much higher in hypertension, 
varying between 34% in cases of mild pre-eclampsia to nearly 70% in severe hypertension.  
Central infarcts also appear to be more associated with significant hypertension (3, 44). 
 
Figure 1.8. Photomicrograph of aggregated villi surrounded by fibrin (left) in placental 
infarction, 38 weeks gestation (x 4 objective). 
 
1.5.5 Villitis of unknown etiology 
 
Villitis of unknown etiology (VUE) is a descriptive term employed to describe chronic 
inflammatory lesions within villi for which the underlying cause is unknown (45). The 
lesions are most often noted in placentas of 32 weeks gestation or later (46). The infiltrate 
has been reported to be composed of CD 68 positive macrophages and a T-cell population 
of maternal origin (47).  Plasma cells are not a feature.  There is believed to be an 
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association between these lesions and intrauterine fetal growth restriction (48) and possibly 
also recurrent reproductive loss (46), although the lesion in these recurrent cases is more 
often now recognized as intervillous histiocytosis (49). 
 
Histological classification of the lesions of VUE is most often based on the number of 
chorionic villi involved and their location within the placental structure. One grading 
system current within the literature separates the process into low-grade and high-grade 
lesions, depending on the location within the placental disc on histological examination 
and the number of chorionic villi involved (46). 
 
The incidence of VUE is often quoted as between 5% to 15% of placentas (50). 
 
1.5.6 Fetal thrombotic vasculopathy 
This lesion is defined as thrombus formation within a chorionic plate or fetal stem artery 
with downstream avascular chorionic villi (51). These histological lesions are illustrated in 
Figure 1.9. While these lesions may be macroscopically visible, the current literature 
favours reliance on the microscopic appearances of the placenta (23). 
 
 
Figure 1.9. Photomicrograph of chorionic plate vessel with luminal fibrin adherent to 
endothelium (left) and downstream avascular chorionic villi (right), 38 weeks gestation (x 
10 objective). 
 
The incidence of the lesion is uncertain, given that some studies include placentas from 
stillbirths, where the vessels show changes which may be better regarded as post-mortem 
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involutionary change.  Where stillbirths are excluded, the incidence of this lesion has been 
reported as between 3 and 10/1000 (22).  
1.5.7 Histological markers of placental abruption 
Placental abruption is a clinical event where the placenta separates prematurely from the 
uterine placental bed; it is associated with a range of adverse perinatal outcomes (52). 
Unifying clinical diagnostic criteria are, however, perceived to be absent from the clinical 
literature, although recently proposed inclusion criteria for a clinical diagnosis of abruption 
include sonographic visualization of abruption, evidence of retroplacental clot and vaginal 
bleeding accompanied by non-reassuring fetal status or uterine hypertonicity.  
The aetiology of abruption is not well understood but there are some reports linking 
abnormal trophoblast invasion of spiral arteries with spiral artery rupture and thus 
premature separation of the placenta. 
Where correlation between clinical findings and pathological observations has been 
attempted, diagnostic concordance has been reported to be poor. The lesion most often 
cited as a pathological finding in abruption is the presence of a retroplacental blood clot on 
macroscopic placental examination: this has been reported in 77% of clinically diagnosed 
cases in one study (53). 
Candidate histological inclusion criteria suggested for a positive diagnosis of abruption 
include haematoma, fibrin deposition, compressed villi and (in older cases) haemosiderin-
laden macrophages. These criteria were found to be only 30% sensitive although 100% 
specific. Of other histological lesions raised as possible associates of clinical placental 
abruption, placental infarction has been identified as reaching statistical significance (49). 
Chorioamnionitis has been associated with clinical abruption, but not with the identified 
histological markers of abruption (53). 
1.5.8 Chronic histiocytic intervillous inflammation 
Chronic histiocytic intervillositis (CHI) is a relatively recently described placental 
abnormality, first reported in 1987 (54, 55).  It is rarely reported within the literature, with 
69 affected pregnancies identified in a recent systematic review examining this lesion with 
respect to recurrence risk (56).  The variability within the literature relating to this lesion is 
perhaps emphasized by the literature search findings of the systematic review: 122 
publications on the initial search were reduced to 6 suitable for inclusion in a systematic 
review. It is of clinical interest in that the lesion is thought to be associated with 
intrauterine growth restriction and fetal death, and may recur in subsequent pregnancies.   
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The histological appearances are characterised by an infiltrate within the intervillous space, 
composed of lymphocytes, histiocytes and monocytes, of maternal origin. When 
characterized immunohistochemically, the infiltrate is reported to be >95% histiocytic 
(CD68 positive), with <5% CD15 positive eosinophil granulocytes and CD3 positive T cell 
lymphocytes and <1% CD20 positive B cells (49, 57). 
The incidence is uncertain; a rate of approximately 40/1000 has been reported for first 
trimester miscarriages with a normal karyotype and between 0.1/1000 and 0.6/1000 for 
second and third trimester placentas. The recurrence risk has been reported as 80% in 
subsequent pregnancies (49). 
1.5.9 Massive perivillous fibrin deposition/maternal floor infarction 
This lesion is characterised by the accumulation of a combination of polymerised fibrin 
and trophoblast-derived extracellular matrix products around large portions of the distal 
villous tree.  This matrix is infiltrated by extravillous trophoblast, believed to be derived 
from a villous trophoblast.  The process is analogous to the development of the anchoring 
villi at the base of the placenta, but when pathological is defined as between 30 and 40% of 
the placental parenchyma being obliterated by perivillous fibrin or (in the case of maternal 
floor infarction), the villi of the entire maternal floor are embedded in fibrin which is at 
least 3 mm thick (58, 59). 
1.5.10 Intervillous thrombus 
This lesion is defined histologically as laminated thrombus lying within the intervillous 
space. Single or multiple lesions may be present, each varying in size from 0.1cm to 5cm. 
The incidence of these lesions in an unselected population has recently reported to be 19% 
(19). 
1.5.11 Plasma cell deciduitis 
 
Plasma cell deciduitis – infiltration of decidualised endometrium by plasma cells – is a 
lesion of uncertain incidence and significance. Infiltration of endometrium by plasma cells 
in the non-pregnant uterus is associated with impaired maternal fertility. In pregnancy, the 
rate of plasma cell deciduitis has been reported to be increased in idiopathic preterm labour 
compared with controls (60), although recognition of the lesion amongst pathologists is 
variable (61).  
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1.5.12 Eosinophilic inflammation  
 
This relatively recently recognized lesion, first described in 2002 (62), involves usually a 
single chorionic vessel surrounded and focally infiltrated by fetally derived eosinophils and 
CD3 positive T cells. A recent large series reports a possible association with villitis of 
unknown etiology (VUE, qv), but no association with adverse fetal outcome (63). 
 
 
 
Figure 1.10. Photomicrograph of chorionic plate vessel wall showing infiltrate of small 
lymphocytes and eosinophils (x 40 objective). 
 
1.5.13 Subacute chorionic plate inflammation 
 
Subacute chorioamnionitis is a lesion which has been described within the literature in a 
small number of publications. The infiltrate is variously described as a subamniotic 
mononuclear cell infiltrate with occasional polymorphs (36), or a more severe lesion with 
mixed degenerative neutrophils and mononuclear cells (64). In the latter study, a positive 
association with chronic lung disease was reported.  
1.6 PLACENTAL PATHOLOGY: MECHANISMS OF DISEASE 
 
1.6.1. Immune responses 
Neutrophil recruitment in acute inflammation is a multistep process (65), with neutrophils 
becoming initially loosely attached to “activated” endothelium in the locality of a stimulus 
via endothelial expression of selectins (66, 67), with subsequent tighter endothelial 
attachment mediated via leukocyte integrins (68). Both selectins and integrins are adhesion 
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molecule families, binding to complementary ligands when converted from low affinity to 
high affinity molecules in an appropriate cytokine environment. 
Identification of specific components of the immune response is often by description of 
specific cell-surface glycoproteins and glycolipids – including, for example, the integrin 
and selectin families identified above. Antibodies raised against cell differentiation or 
clusters of differentiation (CD) molecules form the basis of immune cell classification 
(69). The immune response involves leukocyte-leukocyte interaction, leukocyte-
nonimmune cell interaction, leucocyte-tissue matrix interaction and leucocyte-foreign 
antigen interaction, via this large collection of cell surface markers, now numbering >300. 
Specific CD subsets identify many specific immune cells: B (70)  and T (71) cells are 
identified both by common markers (CD20 and CD 79a for B cells, CD 3 for T cells (69) 
and specific markers identifying B and T cell subsets – for example, T regulatory cells (72, 
73). 
Acceptance that the histological changes of chorioamnionitis and funisitis are attributable 
to infection is virtually universal, with a large number of studies linking this histological 
finding to ascending maternal genital tract infection/colonization (74-76). Previous 
candidate factors such as fetal hypoxia, changes in the pH of the amniotic fluid or of the 
irritant effects of meconium have been rejected on the basis of experimental study. 
The cellular components of the inflammatory response in villitis of unknown etiology 
(VUE) have been demonstrated to be cells of monocyte/macrophage lineage admixed with 
T cells (77). The chronic inflammatory response underlying this observation is also 
induced by expression of various cytokines (eg interleukin 1, interferon γ and tumour 
necrosis factor α) and cell surface adhesion molecules, interacting to induce lymphocyte 
and monocyte migration. It should be noted that the underlying event inducing cell 
migration in non-infectious villitis is unknown. 
The complement system forms part of the humoral immune system. It is conventionally 
described in terms of classical (antibody-activated) and alternative (antigen-activated) 
pathways, with a third, lectin-activated, pathway also existing. All complement pathways 
are centred around activation of C3. The classical pathway is activated by antibody-antigen 
interaction and immune complex deposition. Carbohydrate ligands (including those found 
on some micro-organisms) and injured tissue undergoing apoptosis and necrosis activate 
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the lectin pathway.  The alternative pathway is activated by cell surface components of 
micro-organisms and by IgG. The pathways are highly complex and involve more than 30 
plasma proteins, interacting with a range of cell surface receptors (78-80). Apparent 
activation of complement systems has been reported in pre-eclampsia (81, 82). 
1.6.2 Impaired perfusion 
As has been noted above, the normal term placental decidua is characterized histologically 
by the presence of transformed maternal vessels. This process begins in the second half of 
the first trimester, with migration of cytotrophoblast from the basal aspect of anchoring 
villi, invading decidua and myometrium (extravillous cytotrophoblast) and forming intra-
luminal cellular plugs within decidual spiral arteries (intravascular extravillous 
cytotrophoblast). The endovascular cytotrophoblast subsequently invades and destroys the 
maternal endothelium and arterial smooth muscle: the endpoint of this process is the 
transformation of small muscular arteries to dilated, thin walled vessels containing 
fibrinoid within their walls (83). 
Failure of this physiological process, with deficient intramural trophoblast invasion and 
hyperplastic (or non-transformed) muscular arteries, has been recognized to be a hallmark 
of pre-eclampsia (84). The initial pathological event is considered most likely to be an 
abnormal immunological interaction between fetal trophoblast and maternal natural killer 
(NK) cells (85). Maternal blood flow into the intervillous space is consequently markedly 
compromised: decreased placental perfusion is thought to interact with maternal 
constitutional factors to result in oxidative stress, endothelial activation and multisystem 
maternal disease (86). 
1.6.3 Oxidative stress 
Oxidative stress is a process universal amongst all aerobically respiring organisms.  The 
high-energy electron transfers taking place within cellular organelles support oxidative 
phosphorylation but also generate reactive oxygen species which are toxic to biological 
molecules within the cell.  The potential pathogenicity of reactive oxygen species was first 
demonstrated in 1952, when it was shown that increases in oxygen pressure could cause 
chromosomal aberrations in radiation-exposed pollen grains (87).  Generation of reactive 
oxygen species (ROS) induces DNA, protein and lipid damage if the homeostatic 
equilibrium between pro-oxidant and antioxidant events becomes unbalanced. Oxidative 
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damage to biomolecules has since been implicated in a wide variety of pathophysiological 
processes in humans, including ageing, neoplasia, degenerative diseases, autoimmune 
diseases and neurological dysfunction (88, 89). The interaction between oxidative stress 
generated within mitochondria and intracellular stress occurring within separate organelles 
such as the endoplasmic reticulum is also likely to be important in pathological processes 
within the placenta (90).   
 
There is an equilibrium within the normally functioning cell between the generation of 
reactive oxygen species and antioxidant defences: loss of balance in this homeostatic 
process may induce cell damage and ultimately cell death. The most common reactive 
oxygen species is considered to be the superoxide anion, resulting from leakage of 
electrons onto molecular oxygen from the respiratory chain within mitochondria. There is a 
shorter electron transport chain within in the endoplasmic reticulum; the formation of 
disulphide bonds during protein folding is an oxidative process and also generates 
superoxide anions. Under conditions of endoplasmic reticulum stress, repeated attempts to 
refold misfolded proteins may take place.  It is recognised that intracellular stress - such as 
hyperoxia, hypoxia or hypoglycaemia - may result in oxidative and endoplasmic reticulum 
stress, with possible subsequent induction of apoptosis pathways (91).  
Understanding of the cell cycle and the pathways involved in endoplasmic reticulum 
homeostasis is useful in evaluating such pathological processes.  A biologically stressed 
tissue will exhibit reduced cellular proliferation and increased cell death, and  
immunohistochemical markers of these processes will identify these processes within 
tissue sections. Amongst the immunohistochemical markers available to characterize these 
processes is cleaved caspase 3. 
Caspase 3 is a target protein, subject to irreversible proteolytic cleavage, in a complex 
network of downstream signalling pathways, triggered by engagement of cell surface 
receptors (92). This is in contrast to conventional signal transduction is mediated by ion 
fluxes, secondary metabolites, protein-protein interactions and post-translational protein 
modifications: these are often subject to phosphorolytic and ubitquinolytic regulation and 
as such are reversible (93). The caspase family (12 caspases have been described to date) is 
best known for its function in apoptosis signalling, although there may also be involvement 
in some inflammatory gene regulation (94). 
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1.7 CURRENT DEFINITIONS OF CLINICAL PRESENTATIONS: CLINICAL 
DEFINITION AND CLINICAL INCIDENCE  
 
As will be further discussed in section 8, clinical definitions of specific obstetric, fetal and 
neonatal disorders can be variable. In this review, definitions and clinical practice current 
within the United Kingdom form the basis for discussion. 
 
1.7.1 Maternal/fetal chorioamnionitis 
 
The clinical criteria for the diagnosis of chorioamionitis include maternal pyrexia (above 
37.8°C), maternal tachycardia, leukocytosis (sensitivity 29-47%, false positive rate 5-
18%), uterine tenderness, offensive vaginal discharge and fetal tachycardia (a rate above 
160 beats/minute) (95). The incidence of clinical chorioamnionitis is reported to be 
between 0.5%-10% of all pregnancies: 1-7% at term and 10-20% of preterm (<33 weeks) 
deliveries (96-98). 
 
1.7.2 Pregnancy-induced hypertension/pre-eclampsia 
 
Hypertensive disorders during pregnancy occur in women with pre-existing 
primary/secondary hypertension, and in women who develop new onset (pregnancy-
induced) hypertension ie blood pressure ≥140/90mmHg after 20 weeks gestatation.   
Pre-eclampsia is defined as pregnancy-induced hypertension with diastolic blood pressure 
≥ 90mmHg on at least 2 consecutive occasions, 4 hours apart, or a single episode of 
diastolic blood pressure ≥ 110mmHg on one occasion, the hypertensive events to be 
associated with proteinuria (greater than 0.3 g/24 hours).   
Severe pre-eclampsia and eclampsia (defined as the occurrence of 1 or more convulsions 
superimposed on pre-eclampsia) are relatively rare, but serious, complications of 
pregnancy, with approximately 0.5% of pregnancies associated with severe pre-eclampsia 
and 0.05% with eclampsia. Eclampsia has a maternal mortality rate of approximately 1.8%, 
with a further 35% of mothers experiencing a major complication (99-101). 
 
1.7.3 Placental abruption  
Placental abruption is a clinical event where the placenta separates prematurely from the 
uterine placental bed; it is associated with a range of adverse perinatal outcomes. Unifying 
clinical diagnostic criteria are, however, perceived to be absent from the clinical literature, 
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although proposed inclusion criteria for a clinical diagnosis of abruption include 
sonographic visualization of abruption, evidence of retroplacental clot and vaginal 
bleeding accompanied by non-reassuring fetal status or uterine hypertonicity (102). 
 
1.7.4 Fetal growth restriction 
Fetal growth restriction is defined as fetal growth which has failed to achieve the true 
growth potential in that pregnancy.  A broader group of fetuses, those small for gestational 
age, includes both growth restricted fetuses and those fetuses which are constitutionally 
small.  Both growth restricted and small for gestational age fetuses are at greater risk of 
stillbirth, birth hypoxia, neonatal complications, impaired neurodevelopment and possibly 
late complications in adult life (including type 2 diabetes and hypertension). 
 
The clinical definition is based on biometry, with the most commonly used threshold that 
of the 10 percentile for abdominal circumference and estimated birth weight on antenatal 
ultrasound scan.  
1.8 EVIDENCE FOR CORRELATION BETWEEN CLINICAL DISEASE AND 
HISTOLOGICAL CHANGES 
 
Evaluation of the current evidence correlating clinical obstetric or neonatal problems with 
placental morphological change is highly problematic. Diagnostic criteria for specific 
clinical problems are very variable within the literature and occasionally clinical problems 
correlated to specific placental findings are referred to descriptively but not defined. There 
is a proliferation of non-standardised terminology and disease entities are often referred to 
without a clear statement as to whether it is the clinical or histological process under 
discussion. 
 
1.8.1 Maternal/fetal chorioamnionitis 
 
Preterm labour accounts for around 10% of all deliveries, having multiple well-recognised 
clinical and epidemiological associations, amongst which chorioamnionitis is clearly 
established (103-106). A small number of studies have examined the question of recurrent 
preterm birth and placental inflammation (107, 108).  These studies are more difficult to 
place in context: the histological scoring systems used for the studies are variable, and fetal 
and maternal inflammatory responses have not always been reported separately. 
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Overwhelming maternal sepsis is occasionally but consistently reported as a complication 
of chorioamnionitis (109).  It is a relatively rare occurrence, forming only a small 
proportion of pregnancy-related intensive-care admissions; prognosis is generally good 
with appropriate treatment. 
 
The associations between chorioamnionitis and stillbirths are controversial (110-113). In 
the specific group of preterm non-macerated stillborn infants with histological evidence of 
an established fetal inflammatory response (see below), it is reasonable to conclude that 
ascending infection was likely to be the underlying cause of the pregnancy loss, by 
precipitating delivery.  This specific group accounts for only around 10-25% of all 
stillbirths (114), with the lower end of the range likely to be most applicable to Western 
populations (112). 
 
The most important pathway relating chorioamnionitis to adverse neonatal outcome 
appears to be the fetal inflammatory response syndrome (115, 116).  The data are, 
however, somewhat paradoxical.  Histological chorioamnionitis is associated with 
improved survival in very preterm infants compared to gestationally age-matched cases 
with no inflammation (117), presumably as a consequence of the fact that preterm delivery 
is associated with ascending infections are otherwise normal infants, whereas those 
delivered preterm for other indications will very likely have other complications such as 
fetal growth restriction.   
 
Assessing the implications of chorioamnionitis for all liveborn infants, born preterm or 
term, continues to be problematic.  A meta-analysis carried out 10 years ago (118)  
reported significant associations between clinical chorioamnionitis and both cerebral palsy 
and periventricular leucomalacia in preterm infants and an association between histological 
chorioamnionitis and periventricular leucomalacia in preterm infants.  For term infants, 
there was a positive association between clinical chorioamnionitis and cerebral palsy.  A 
subsequent extended meta-analysis (119) reported an association between recorded clinical 
chorioamnionitis and cerebral palsy with a random effects model, and a more recent meta-
analysis (120) reported associations between both clinical and histological 
chorioamnionitis and cerebral palsy in studies predominantly, but not exclusively, of 
preterm infants. 
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1.8.2 Pregnancy-induced hypertension/pre-eclampsia 
 
Both clinical and experimental studies have reported links between clinical pregnancy-
induced hypertension, pre-eclampsia and eclampsia and placental morphology. A 
retrospective case series has reported correlation between the clinical severity of the 
maternal hypertensive disorder and the degree of placental infarction present: infarction 
involving ≥5% of placental tissue was found in 39.7% of severe pre-eclampsia, 17.1% of 
mild pre-eclampsia and 5.1% of normal controls. When comparing placentas in severe pre-
eclampsia, mild pre-eclampsia and normal mothers, there was an increase in the presence 
of any infarction and decidual arteriopathy (121). 
 
A similar study, evaluating placentas from patients with severe pre-eclampsia with and 
without hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome has 
reported that infarction, intervillous thrombosis and abruption were more common in the 
pre-eclampsia group than in the HELLP group (122). 
 
Analysis of placental microarchitecture of capillary loops in placentas from growth-
restricted fetuses has shown a reduction in capillary loop number, with significantly 
increased length and fewer branches, compared to controls. It is suggested that these 
findings are consistent with an increase in fetoplacental vascular impedance at the capillary 
level and may account for impaired gas and nutrient exchanges in pre-eclampsia (95). 
 
1.8.3 Placental abruption 
 
Positive associations between chorioamnionitis and placental abruption in preterm and 
term births are reported within the literature (53, 55).  The hypothesis is that localised 
inflammation processes disrupt normal placental attachment.  It should, however, be 
acknowledged that many cases of abruption are associated with other, well validated, 
epidemiologically derived factors such as previous abruption, hypertension (as noted 
above), ethnicity, smoking and cocaine use (123-125). 
 
1.8.4 Fetal growth restriction 
 
Fetal growth restriction is most commonly defined as fetal growth < 10
th
 centile for 
gestational age (126) , but growth below the 3
rd
 centile has also been proposed as a more 
reliable indicator for associated perinatal morbidity (127). A number of authorities have 
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also noted that basing assessment of growth entirely on a population basis misclassifies a 
number of  fetuses as either small or large for gestational age (128-130). 
The most commonly reported specific placental lesions reported in association with fetal 
growth restriction include those lesions associated with maternal hypertension and also 
high-grade villitis of unknown etiology and chronic intervillous histiocytosis. 
 
Early onset pre-eclampsia has been reported to be more strongly associated with specific 
placental lesions (infarction and decidual vasculopathy) than later onset pre-eclampsia (30, 
131). Villitis of unknown etiology is repeatedly reported to be associated with growth 
restriction, albeit with lower grade lesions of more doubtful signficance (46, 132, 133). 
Chronic intervillous histiocytosis has been  reported in to be associated with growth 
restriction (27), although as discussed elsewhere this lesion may be more associated with 
recurrent pregnancy loss (49, 134). 
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1.9 CONCLUSIONS 
 
 
 Normal placental development is well understood. The end of the first trimester 
marks a shift from histiotrophic-fuelled growth and development to maternal 
perfusion-mediated growth and development. 
 The normal macroscopic appearances of the placenta are defined in terms of 
size, shape, weight and cord insertion site. 
 The normal microscopic appearances of the placenta are defined as micro-
anatomical compartments: cord, free membranes, chorionic plate, intervillous 
space, chorionic villi and maternal decidua. 
 Macroscopic abnormalities of the placenta include infarction, intervillous 
thrombus formation and fetal thrombotic vasculopathy.  
 The significance of variations in placental shape (eccentricity)  and centrality of 
cord insertion site is uncertain. 
 Microscopic abnormalities of placenta include chorioamnionitis and funisitis, 
impaired perfusion, villitis of unknown etiology, fetal thrombotic vasculopathy, 
placental abruption, chronic histiocytic intervillous inflammation, massive 
perivillous fibrin deposition and maternal floor infarction, intervillous 
thrombus, plasma cell deciduitis, eosinophilic inflammation and subacute 
chorionic plate inflammation. 
 Mechanisms of disease in placental disorders include acute and chronic 
inflammatory pathways, complement activation and impaired perfusion with 
subsequent oxidative stress. 
 Associations between placental lesions and adverse clinical outcomes have 
been reported in the context of both prospective and retrospective studies. 
Findings are often confusing, conflicting and difficult to apply to clinical 
practice. 
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______________________________________________________ 
 
CHAPTER TWO: MATERIALS AND METHODS 
______________________________________________________ 
 
 
Summary: 
 
 
 Study design, recruitment of subjects and clinical data collection 
 Macroscopic placental examination  
 Computer based image analysis techniques  
 Histological reporting protocols 
 Immunohistochemical techniques 
 Adaptation of systematic review construct  
 Statistical analysis of data 
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2.1 STUDY DESIGN 
 
The study design was single-centre, prospective, and of an unselected population, approved 
by Cambridgeshire Research Ethics Committee (Ref.no:07/Q0106/51, see Appendix  A). 
All potential subjects were offered a patient information leaflet and written consent 
(Appendix B) was obtained from all participants within the study. Recruitment was carried 
out over a 13 month period from 2007 to 2008. Only subjects with an ongoing singleton 
pregnancy were eligible for inclusion in the study. 
2.2 MATERIALS AND METHODS 
 
2.2.1 Collection of placentas 
At delivery, placentas delivered from participants consenting to inclusion in the study were 
inspected grossly by the delivering clinician/midwife, in keeping with pre-existing local 
clinical guidelines. Specific guidance relating to this study, to support the local midwifery 
staff, was provided in sluice areas. Briefly, placentas were placed in a labelled double bag 
within 20 minutes of delivery, which was kept in a dry, clean 1-2 litre plastic container 
with an airtight lid and in a fridge with the temperature maintained at 4-6C. Daily 
transfers from the obstetric to the histopathology department were undertaken, together 
with a study-specific request form (Appendix C). 
2.2.2 Collection of clinical data 
Obstetric and neonatal outcomes for this project were collected onto a database specifically 
created for the study. The database was held on two password-protected servers (one for 
obstetrics and one for histopathology) within Addenbrooke’s Hospital. A broad range of 
data for each mother and infant was collected, including demographics, pre-conception 
history, events in pregnancy, delivery and immediate neonatal outcome. The clinical 
parameters recorded for each mother and infant are summarized in Table 2.1 
Collection of placentas and recording of clinical data were carried by Dr Sangeeta Pathak, 
clinical research fellow, Department of Obstetrics and Gynaecology, Addenbrooke’s 
Hospital, who undertook a clinically based research project on this cohort.  
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Maternal characteristics Infant characteristics 
maternal age sex 
parity gestational age 
ethnic origin birth weight 
pre-existing essential hypertension apgar scores at 1 and 5 minutes 
smoking status birth weight < 10th centile 
pre-conception diabetes suspected neonatal sepsis 
hypertensive disorders of pregnancy neonatal acidosis 
suspected maternal chorioamnionitis admission to neonatal intensive care 
clinical abruption  
onset of labour  
mode of delivery  
Table 2.1 Clinical parameters recorded to assess maternal and infant outcomes 
 
2.2.3 Protocol for macroscopic placental examination 
Placental weight is usually routinely recorded as part of the macroscopic examination of 
the placenta, and is routinely recommended in guidelines issued in both the US and the UK 
(135, 136). It should be noted, however, that while fetal weight and placental weight tend 
to be correlated, placental weight alone may not be a useful predictor of function (137), 
with decreased placental/fetal weight ratios possibly reflecting the endpoint rather than the 
underlying cause of restricted growth of the fetal-placental unit in any individual 
pregnancy. There is equally limited evidence to support independent significance for 
placental measurements, which are closely correlated with placental weight (138). 
Macroscopic assessment of the normal and abnormal (infarcts, fibrin, intervillous thrombus 
etc) placental cut surface is described in the US and UK guidelines cited above. 
 
For this study, the available publications describing placental examination were reviewed 
in the context of the study aims and objectives. A protocol was agreed within the research 
team (Appendix D).  
Briefly, placentas were photographed, examined and blocked for microscopic examination 
by one of two researchers, assisted by a research assistant recording the information on a 
standardised proforma (Appendix 4). The cord was removed at the point of insertion into 
the placental disc. Blood was drained from the disc via the cord insertion point and any 
adherent clot removed from the maternal surface. A trimmed, drained weight was recorded, 
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together with measurements in 3 dimensions. The presence or absence of infarcts, 
intervillous thrombus, haematoma, macroscopically identifiable fibrin and maternal surface 
thrombus/blood clot was noted.  The placenta was then sliced in parallel 1 cm intervals. 
Photography was undertaken by recording pictures of the intact fetal and maternal 
surfaces, with the umbilical cord detached and included in the picture.  A further 
photograph was taken following parallel 1 cm slicing, to record the appearances of the cut 
placental surface. 
The cord was examined by recording length, diameter, coiling index (turns/length), 
direction of cord spiral, cord insertion site of the presence of absence of true cord knots.   
The standard blocks sampled for histological examination included 3 of cord (maternal 
end, fetal end and central), membranes (including free edge), 3 full thickness central 
parenchymal blocks, 1 full thickness peripheral parenchymal block and 2 of the maternal 
surface.  Any focal specific lesion was also sampled for histological examination. 
Placental prosection was divided between the author and Dr Sangeeta Pathak, clinical 
research fellow, as part of the clinical research project noted above. 
2.2.4 Eccentricity and cord centrality indices 
Calculation of placental eccentricity and cord centrality indices was undertaken by Dr 
Sangeeta Pathak, clinical research fellow, again as part of the clinical research project 
noted earlier in this Chapter. 
Briefly, photographs of the fetal surfaces of the placentas involved were analysed by 
computer based analysis. The widest possible X and Y axes, intersecting at right angles, 
were created. These are represented by A and B in the diagram below. The cord insertion 
point was mapped by two further X and Y axes, parallel to the originals, but intersecting at 
right angles at the cord insertion point (C and D in the diagram below). Mathematical 
formulae were created to calculate: 
1. distance of umbilical cord insertion from the centre 
2. cord centrality index (the smaller the index, the closer the cord insertion point to 
the centre) 
3. eccentricity index, between 0 and 1 (a perfect circle has a value of 0; the more 
elliptical the shape, the closer to 1). 
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Figure 2.1. Diagrammatic representation of placental ellipse, showing axes intersecting at 
the centre of the ellipse (A and B) and at the cord insertion site (C and D). 
 
2.2.5 Analysis of infarction images 
The percentage of parenchymal infarction in the macroscopically identified infarct cases 
was analysed using ImageJ software, public domain Java based image analysis software 
developed by the National Institute of Health (139). The photographs of infarct cases were 
reviewed, with the total cut surface area and area of cut surface infarction determined as 
follows: 
1. Set scale: analyze>set scale>measure known distance on scale included in 
photograph. 
2. Known distance entered, calibrated with given number of pixels, scale set 
3. Freehand tool selected, outline of each slice made: area measured: 
analyze>measure>area. 
4. Repeat process for infarcts: freehand tool selected, outline of each infarct made: 
area measured: analyze>measure>area. 
  
A C 
B 
D 
Cord insertion site 
Centre of placental 
ellipse 
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2.2.6 Protocol for processing tissue blocks 
Tissue blocks were processed, sectioned and stained in accordance with standard 
laboratory protocols: following 24 hours fixation in 10% buffered formalin, standard tissue 
processing (Excelsior) and paraffin embedding, a full face tissue section was cut from each 
paraffin embedded tissue block. Standard haematoxylin and eosin staining was then 
undertaken. Following appropriate crosschecks between block, slide and study number, 
slides were issued to the reporting pathologist.  Residual placental tissue was disposed of 
(following checks to confirm successful processing of tissue blocks) by incineration. The 
laboratory protocols adhered to are archived electronically as standard operating 
procedures (SOPs) within Addenbrooke’s Hospital Histopathology Department and are 
subject to external review and audit by Clinical Pathology Accreditation UK (most recent 
CPA accreditation November 2011). Tissue block processing, cutting and staining were 
undertaken by members of the biomedical science team in the Department of 
Histopathology, Addenbrooke’s Hospital. 
 
2.2.7 Histology reporting protocols - initial analysis 
 
Many previous studies of placental pathology have, as discussed in Chapter 1, been 
undermined by insufficiently rigorous definitions of histological abnormalities. A reporting 
schedule was thus agreed between the two lead reporting pathologists (Dr FA Jessop 
(FAJ), Addenbrooke’s Hospital and Professor NJ Sebire (NJS), Great Ormond Street 
Hospital for Sick Children), reviewed and supported by Dr CE Hook, consultant 
paediatric/perinatal pathologist, Addenbrooke’s Hospital. The objective of this first round 
of analysis was to place each case in one of eleven diagnostic categories which were found 
to be robustly reproducible, in line with current clinical reporting practice in the home 
institutions of both pathologists and supported by the current best evidence for the defining 
histological characteristics of each diagnostic group:  this evidence has been discussed at 
length in Chapter 1 and the morphological features are summarized in Table 2.1. It should 
be noted that this phase of analysis thus excluded some placental histological changes (eg 
syncytial knots) where the current literature lacks sufficiently clear definitions and the 
reproducibility of the diagnostic criteria is doubtful (3).  
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Histological diagnosis Morphological characteristics 
no significant histological abnormality. normal membranes, umbilical cord, 
maturation of chorionic villi within 
normal limits, normally transformed 
maternal vessels 
features of ascending genital tract infection. infiltration of neutrophil or 
eosinophil leucocytes into extra-
placental membranes and/or 
chorionic plate and/or umbilical 
cord; apparent at low power 
microscopy 
features of chronic placental underperfusion, 
including pre-eclampsia * 
distal villous hypoplasia 
placental infarction 
maternal vasculopathy 
villitis of unknown etiology focal mononuclear cell infiltration of 
chorionic villi ± fibrinoid necrosis; 
apparent at low power microscopy 
fetal thrombotic vasculopathy * thrombi in stem villous arterial 
lumina ± mural fibrin in stem villous 
arteries ± downstream avascular villi 
features of acute abruption * retroplacental blood-clot 
chronic histiocytic intervillositis intervillous infiltrate of mononuclear 
cells not associated with villous 
infarction 
massive perivillous fibrin deposition * fibrin-entrapped, widely separated 
terminal/stem villi ; fibrin obliterates 
intervillous space 
intervillous thrombus * laminated thrombus within 
intervillous space 
chorangiosis ≥ 10 capillary cross-sections 
involving ≥ 10 villi in ≥ 2 separate 
areas of the placenta 
chorangioma * discrete nodule of small thin walled 
blood vessels within loose 
perivascular stroma 
Table 2.2: Histological characteristics of diagnostic groups 
 
 
 
* Sampling protocols were drawn up to ensure that lesions which rely on correlation with 
the placental macroscopic findings were reliably and representatively sampled for 
histological assessment, please see Appendix 4. 
 
A pilot cohort of 100 cases was reported, within the framework of this classification, 
independently by FAJ and NJS, supported by two rounds of face to face consensus 
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meetings. Interobserver agreement was reached in all 100 cases following this process. All 
study cases were then reported by one of the two researchers (including the 100 pilot cases, 
which were returned to the pool and randomly distributed between the two reporting 
pathologists).   
 
2.2.8 Histology reporting protocols – sub-analysis 
 
Sub-analysis of two histological groups  - histological features of ascending infection and 
villitis of unknown etiology - was undertaken in this study.  
This was preceded by histological review of all study cases initially classified as showing 
no significant histological abnormality. The principal objective of this rescreening of cases 
was to capture all cases showing degrees of inflammation which had fallen short of the 
original diagnostic criteria for a pathological diagnosis, and had thus been placed in the 
diagnostic category of “no significant histological abnormality” in the first round of 
analysis. Cases were then placed in additional subgroups as follows in Tables 2.3, 2.4 and 
2.5. 
 
2.2.9 Composite tissue blocks for immunohistochemistry 
 
Tissue blocks identified for immunohistochemistry were prepared as follows: 
The abnormal area within the tissue section was identified and marked on the H&E-stained 
slide with a permanent marker pen. Correlation with the paraffin wax-embedded block was 
made and the paraffin wax-embedded block marked in the same area, again with a 
permanent marker pen. The abnormal area within the paraffin block was excised with a 
tissue punch, 2mm diameter. Composite blocks containing up to 20 separate cases were 
prepared by embedding the identified abnormal tissues in paraffin wax, together with 
similar 2mm punch biopsies of tonsil, placenta, kidney and liver. These tissues acted both 
as orientation guides and as internal staining controls. 
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Histological diagnosis Morphological characteristics 
plasma cell deciduitis plasma cells within placental decidua 
(61) 
eosinophilic inflammation  small lymphocytes and eosinophils 
associated with chorionic plate 
vessel(s) (62) 
subacute chorionic plate inflammation small lymphocytes and/or histiocytes 
within chorionic plate (64) 
Table 2.3: Diagnostic characteristics of additional histological categories for sub-analysis 
 
 
Micro-anatomical location of 
inflammation 
Morphological characteristics 
free membranes collections of polymorphonuclear 
leukocytes within amnion/chorion, > 
5 per cluster 
umbilical cord migration of polymorphonuclear 
leukocyte(s) within endothelium, 
muscularis or Wharton’s jelly 
subchorionic fibrin collections of polymorphonuclear 
leukocytes within subchorionic fibrin, 
> 5 per cluster 
chorionic plate migration of polymorphonuclear 
leukocyte(s) within endothelium or 
muscularis 
Table 2.4: Subclassification of cases showing histological features of ascending infection 
 
 
Variant of VUE Morphological characteristics 
focal low-grade VUE clumped clusters of chorionic villi 
infiltrated by small lymphocytes and 
histiocytes, < 10 chorionic villi per 
cluster, changes present on one slide 
only 
multifocal low-grade VUE clumped clusters of chorionic villi 
infiltrated by small lymphocytes and 
histiocytes, < 10 chorionic villi per 
cluster, changes present on > one slide  
patchy high-grade VUE clumped clusters of chorionic villi 
infiltrated by small lymphocytes and 
histiocytes, >10 chorionic villi per 
cluster, changes present on one slide 
only 
diffuse high-grade VUE clumped clusters of chorionic villi 
infiltrated by small lymphocytes and 
histiocytes, >10 chorionic villi per 
cluster, changes present on > one slide 
Table 2.5: Subclassification of cases showing villitis of unknown etiology 
 
 
      
 Page |  36 
2.2.10 Immunohistochemical staining 
 
The primary antibodies applied to selected cases were as summarized in Table 2.6 below 
 
Primary 
antibody 
Raised In Dilution Antigen 
retrieval 
Supplier Control 
 
CD3 Mouse ready-made 
heat 20 
mins pH9 Leica tonsil 
 
CD20 Mouse 1:1000 
heat 20 
mins pH9 DAKO tonsil 
 
HLADR Mouse 1:3000 
heat 20 
mins pH6 DAKO tonsil 
 
CD68 Mouse 1:200 
enzyme 1 - 
10 mins DAKO tonsil 
 
C4d Rabbit 1:40 
heat 20 
mins pH9 Biomedical tonsil 
 
cleaved caspase 3 Rabbit 1:50 
heat 20 
mins pH6 Cellsignalling appendix 
 
ICAM  Mouse 1:25 
heat 10 
mins pH6 Leica tonsil 
 
P selectin  Mouse 1:100 
heat 20 
mins pH6 Leica tonsil 
 
Fox P3 Mouse 1:50 
heat 20mins 
pH6 AbCam tonsil 
Table 2.6: primary antibodies, dilution, antigen retrieval, supplier and control tissue for 
immunohistochemical staining. 
 
The secondary antibody used was a DAB-conjugated rabbit antimouse antibody used at a 
dilution of 1:100.  
Immunohistochemical staining was carried out in accordance with widely published 
protocols (140). 
 
2.2.11 Scoring of immunohistochemistry 
 
Villous area: 
The area of placental villi included in each 2mm punch biopsy was calculated by use of 
ImageJ software (139). Each punch biopsy (within a microarray of up to 20 cases) was 
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photographed, with a graticule scale also photographed at the same magnification as the 
cases.  
The photomicrographs were analysed as follows (see Figure 2.1): 
 
1. Set scale: analyze>set scale>measure known distance on photomicrograph of scale 
included in photograph. 
2. Known distance entered, calibrated with given number of pixels, scale set. 
3. Open photomicrograph of case. Areas of non-villous tissue (fibrin, accumulations 
of red blood cells, included chorionic plate etc) all identified. Freehand tool 
selected, outline of each non-villous area made: edit>cut. 
4. Resulting image (with villous tissue only) modified to 8-bit image: image>type>8-
bit. 8-bit image made binary: process>binary>make binary. 
5. Resulting black and white image reviewed: if villi closely packed: 
process>binary>watershed. 
6.  Area of villi calculated: analyze>analyze particles. 
 
H&E    8 bit image  binary image 
 
Figure 2.2: Processing of image for image analysis: H&E image → 8 bit image →  
binary image (x 2 objective). 
 
Immunohistochemically stained slides were scored by recording positively staining 
cells/membranes in each section with a tally counter and dividing the number of positive 
counts by the villous area calculated in mm
2
.  
 
2.2.12 Systematic reviews 
The systematic review approach taken to support this study was based on a standardised 
Cochrane review systematic review model (141). The methodology is described in detail in 
Chapter 4.  
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In summary, specific criteria were set for inclusion and advanced searches of MEDLINE 
and EMBASE were undertaken. Review of abstracts was independently undertaken by FAJ 
and NJS. Hand searching of relevant journals, searching of returned manuscript reference 
lists and direct email/postal approach to authors of conference abstracts was also 
undertaken. Data were extracted onto standardised forms. 
 
Evaluation of study quality preceded data extraction. Analysis of the data were carried out 
using RevMan software (Review Manager v5.1.6). (142). 
 
2.2.13 Statistical analysis of data 
 
The statistical techniques used in this study are derived from printed material and software 
supplied in courses run by the University of Cambridge Centre for Applied Medical 
Statistics (143) and the University of Nottingham Systematic Review Course (142, 144). A 
standard statistical text was also referred to (145). Statistical analysis was undertaken with 
Microsoft Excel, GraphPad software (146), RevMan software (142) and the open source 
epidemiological web resource, OpenEpi (147). 
 
Chi
2 test, Fisher’s exact test, Mid-p exact, Mantel-Haenszel test 
 
These tests analyse data presented in a contingency table, an example of which is given 
below 
 
 Observation X Observation Y Total 
Group A 200 250 450 
Group B 100 450 550 
Total 300 700 1000 
Table 2.7: Example of contingency table, with illustrative values 
 
Chi
2 testing and Fisher’s exact test measure the significance of association between the two 
classifications in the table (observation X and observation Y).  
 
Both the chi
2  
test and Fisher’s exact test analyse categorical data (eg placental finding 
present  - Group A, or absent - Group B) with numerical data (numbers in each group).  
The counts are presented in a contingency table with analysis of counts in the context of 
predetermined level of significance and degrees of freedom (based on the numbers of 
columns and rows). Chi
2 
testing makes assumptions about the sampling distribution of the 
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population, and so Fisher’s exact test (which becomes unbalanced with large populations) 
is used with smaller populations. By convention, Fisher’s exact test is used when a cell in 
the contingency table contains a value of 5 or less. Many statistics programmes provide 
both Fisher’s exact and mid P exact values. Fisher’s exact test is “conservative” – it 
requires more evidence than is necessary to reject a null hypothesis. Mid P is more 
“powerful”, is better suited to larger populations, and delivers a p value that is closer to the 
p value for entirely uncorrected data. In this study, the possible conflict between small 
numbers (in individual subgroups) and large numbers (the whole study) is addressed by 
examining, where appropriate, both Fisher’s exact and mid P values.  
 
The Mantel-Haenszel test is used in meta-analysis, providing a pooled odds ratio (qv) 
across independent studies, by analyzing data entered in multiple 4x4 contingency tables. It 
thus tests whether the overall degree of association is significant. When combined with a 
chi
2  
test, data can be assessed for equality as well as a pooled odds ratio.  
 
D’Agostino-Pearson normality test 
 
A completely normally distributed population is expressed graphically as a bell-shaped 
curve, symmetrically distributed about the mean. The spread depends on the variable under 
study, but ~ 68% of observations lie within 1 standard deviation of the mean, and 95% of 
observations lie within 2 standard deviations of the mean. A data set may be tested for 
“skewdness” and deviation from normal distribution with a normality test formula, which 
calculates the variation of each value from the value expected with a Gaussian distribution, 
and computes a single p value from the sum of these discrepancies.  
 
Mann-Whitney test 
 
The Mann-Whitney test compares the median values of two groups – with a small p value, 
the null hypothesis that there is no difference between the median values of two groups can 
be rejected. A large p value does not imply that the medians are the same, but provides no 
statistical evidence that they differ. Gaussian distribution is not necessary for this analysis. 
 
Odds ratio and 95% confidence interval 
 
An odds ratio is commonly expressed as a statistical “best guess” as to the size and 
direction of the effect of an experimental intervention compared to a control intervention. 
In this study, this concept is adapted in that the “intervention” takes the form of a specific 
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placental finding with the control group formed by those cases in the study group not 
showing this finding. 
The odds ratio is presented as a single number – a point estimate. A positive odds ratio 
implies a positive association with a given clinical outcome, while a negative odds ration 
implies a negative (or protective) association with a given clinical outcome. The odds ratio 
is, however, expressed in the context of a 95% confidence interval. Very wide confidence 
intervals imply that the true effect is unclear, and a confidence interval which crosses zero 
implies that there is no clear evidence for a significant odds ratio in either direction. 
 
One way ANOVA and Bartlett’s test 
 
This statistical test assesses the equality of three or more means, with the null hypothesis 
that the population means are equal. This test assumes normal distribution, and will 
identify at least one mean which is different – although not where the difference lies. The 
ANOVA test also assumes equal variance (the spread of values from the mean) within each 
population, but this can be confirmed by applying Bartlett’s test to the data sets.  
 
P values (one tailed and two tailed) 
 
The p value is a numerical expression of the outcome of a null hypothesis (H0) test. For 
example, in this study, observed placental findings are analysed in the context of clinical 
outcome, generating the null hypothesis that placental finding A is not associated with 
clinical outcome B. Rejection of the null hypothesis requires a p value less than a specific 
value, conventionally < 0.05 – implying that there is a probability of 0.95 that rejection of 
the null hypothesis is the correct decision. In this study, given the large number of 
calculations undertaken, p values around 0.05 are carefully reviewed. 
 
The p value generated from the testing of any null hypothesis can be expressed as one-
tailed or two-tailed. One-tailed p values are used in a context only where there is pre-
existing statistical evidence for an effect that is unidirectional. In this project, a one-tailed p 
value would imply, for example, that placental finding A is already known (from pre-
existing analysis of the project data) to be positively associated with clinical outcome B. 
This does not apply to the data in this project and so two-tailed p values, which test for 
statistical significance in both directions, are used throughout. 
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Spearman’s rank correlation coefficient 
 
Spearman’s rank correlation coefficient measures the strength of association between two 
ranked variables. This test applies to monotonic variables: where one variable increases, a 
second increases/decreases. The value generated, rs, lies between +1 (perfect association), 
0 (no association) and -1 (perfect negative association). The data do not have to conform to 
a particular pattern of distribution for this analysis (non-parametric). 
 
T test 
 
The t test compares the means of two groups for statistical significance, while taking into 
account the spread of the data (standard deviation) and number of subjects in each group 
(degrees of freedom).  
 
z scores 
 
z scores standardize measurements from different groups, by transforming raw values to a 
score expressing the standard deviation from the mean for each data value. Initial 
calculation of the mean and standard deviations for each data group are thus required. The 
resulting values are often thus more informative than comparison of means between 
groups, as each data value is indexed.  
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2.3 CONCLUSIONS 
 
 
 Recruitment protocols drawn up 
 Clinical data recorded on a password protected NHS Trust server1 
 Placentas examined in accordance with a standardized protocol1 
 Analysis of placental eccentricity (shape) and cord insertion undertaken1 
 Computer based analysis of photographs showing placental infarction undertaken 
 Tissue blocks from the prosected placentas processed to paraffin2  
 Haematoxylin and eosin2 and immunohistochemical staining3 of tissue sections  
undertaken 
 Diagnostic criteria for a range of placental lesions drawn up, with two rounds of 
reporting
4
: the first in accordance with current clinical reporting protocols, the 
second to identify all possible histological lesions 
 Computer based analysis and scoring of immunohistochemical slides undertaken 
 Systematic review methodology reviewed and adapted for histopathology-based 
research 
 Statistical tests selected for analysis of project data 
 
 
 
 
 
 
 
 
 
 
1. Collection of clinical data, analysis of placental eccentricity and cord insertion site and 
approximately 50% of placental prosection was undertaken by Dr Sangeeta Pathak, 
Clinical Research Fellow, Department of Obstetrics and Gynaecology, Addenbrooke’s 
Hospital. 
2. Tissue block processing, cutting and H&E staining were carried out by members of the 
biomedical science team, Addenbrooke’s Hospital. 
3. Immunohistochemical micro-array tissue blocks and immunohistochemical staining was 
undertaken by Ms Rebecca West, biomedical scientist, Great Ormond Street Hospital. 
4. The initial round of reporting was undertaken jointly between Dr F Jessop and Professor NJ 
Sebire.  
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______________________________________________________ 
 
CHAPTER THREE: BASELINE CLINICAL AND 
PLACENTAL CHARACTERISTICS OF STUDY 
POPULATION 
______________________________________________________ 
 
 
 
Summary: 
 Demographic attributes and clinical characteristics of subjects 
 Obstetric and neonatal outcomes 
 Placental macroscopic findings 
o Cord coiling index 
o Macroscopically identified infarcts 
 Placental histological findings 
o No significant abnormality 
o Features of ascending genital tract infection 
o Features of chronic placental underperfusion 
o Villitis of unknown etiology 
o Fetal thrombotic vasculopathy 
o Chronic histiocytic intervillositis 
o Massive perivillous fibrin deposition 
o Intervillous thrombus 
o Chorangiosis 
o Chorangioma  
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3.1 INTRODUCTION 
 
In this study, the target population was all women with an ongoing singleton pregnancy 
during the recruitment period 2007-2008. The study population was thus formed by those 
subjects available to the researchers involved in this study – ie women booking for delivery 
in the Rosie Hospital, Cambridge. Finally, the sample population constituted those women 
giving informed written consent to inclusion in the study during the recruitment period.   
 
Sampling error was controlled for as much as possible by recruiting a large number of 
subjects to the study. On completion of the study, retrospective comparisons with 
incidence of the clinical outcomes of interest in this study were made with data available 
within published literature. 
 
The study took the form of an unselected prospective cohort study. The cohort study is an 
effective tool in the identification of risk factors causing a particular outcome and was thus 
the most appropriate form of study (compared to, for example, a case control study) to 
answer the specific research question posed by this particular study: to determine whether 
any of a range of different macroscopic and microscopic findings within the delivered 
placenta are associated with specific obstetric and neonatal outcomes. Drawbacks of the 
cohort study include the relatively high financial and professional resources required for 
successful completion, and the difficulties in studying specific conditions with a low 
incidence within the target population. 
3.2 METHODS 
 
Consecutive subjects were recruited from their contact with obstetric services in the Rosie 
Hospital. Posters were placed in patient areas (eg antenatal clinics, ultrasound department, 
wards and delivery unit). Excluded subjects were those unable to give informed consent, 
those with multiple pregnancy or those found not to have an ongoing pregnancy on 
booking. Women were given study information leaflets on presentation at booking, with 
consent for participation obtained largely on presentation to the delivery unit.  
 
There was thus a relative bias in recruitment to relatively uncomplicated term pregnancies: 
those women presenting in preterm labour, or with obstetric emergencies, tended to be lost 
to recruitment given the urgency of dealing with the presenting clinical problem. The 
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advantage to this bias is that the data collected represent the findings in a largely healthy, 
largely term population, allowing study of specific placental lesions biased away from 
adverse clinical outcomes. The study was based on consecutive recruitment – all those 
subjects consenting to involvement were included.  
 
Data entry was made onto secure servers within the Departments of Obstetrics and 
Histopathology, with the databases united only on completion of all data collection: until 
that point, all researchers involved in the study were blinded to all findings within the 
study other than their own individual observations. 
 
3.3 STATISTICAL ANALYSIS 
 
The initial data sets are given below. Data are grouped according to type – discrete or 
continuous variables etc.  Limited statistical analysis has been carried out on the initial data 
sets: where appropriate, percentage calculations have been performed, mean values are 
presented with standard deviations, and infarct data are presented as a frequency 
histogram. 
 
3.4 RESULTS 
 
3.4.1 Demographics 
 
The demographics and clinical characteristics of the study population are given in tables 
3.1, 3.2 and 3.3. The population studied, with a bias towards women presenting close to 
term in uncomplicated labour as noted above, was that of a predominantly low-risk 
Caucasian population with a smoking rate of 9%.   
 
Study population 1119 
Mean age 31 (SD 5.75) 
Primiparous subjects 535 
Caucasian subjects 1013 
Pre-existing (essential) hypertension 5 
Smokers 102 
Type 1 diabetes 4 
Table 3.1 Baseline population characteristics of 1119 subjects 
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3.4.2 Clinical outcomes 
 
The clinical outcomes selected for the study included a range of known and potentially 
adverse outcomes, to ensure that as many associations as possible between possibly 
significant macroscopic/microscopic placental lesions and clinical compromise were 
detected. For example, the threshold for neonatal acidosis was set at pH 7.2 rather the more 
often quoted pH 7.0 (148), to maximize the detection of marginally compromised 
neonates. The clinical outcomes are summarized in tables 3.2 – 3.4.  
 
Clinical outcome Percent (number of cases) 
Pregnancy-induced hypertension 2.4 (27) 
Pre-eclamptic toxaemia of pregnancy 2.1 (24) 
Antepartum intra-uterine growth restriction 1.1 (12) 
Suspected maternal chorioamnionitis 0 (0) 
Clinical abruption 0.08 (1) 
Spontaneous onset of labour 63 (710) 
Induced onset of labour 20 (218) 
Elective lower segment caesarian section 14 (157) 
Mode of onset of labour not recorded 3 (34) 
Spontaneous vertex delivery 63 (705) 
Assisted vaginal delivery 12 (130) 
Emergency lower segment caesarian section 11 (127) 
Gestation ≥ 37 weeks 97 (1085) 
Gestation ≤ 37 weeks 3 (34) 
Table 3.2: Obstetric outcomes in 1119 singleton deliveries 
 
Mean birth weight, g 3485 (SD 543) 
Mean birth weight, boys, g (n=596) 3460 (SD 486) 
Mean birth weight, girls, g (n=523) 3510 (SD 510) 
Mean Apgar score @ 1 minute 9 (SD 0.88) 
Mean Apgar score @ 5minutes 10 (SD 0.59) 
Table 3.3: Neonatal outcomes (means and standard deviations) in 1119 singleton 
deliveries 
 
Clinical outcome Percent (number of cases) 
Birth weight < 10th centile 9.5 (106) 
Birth weight < 10th centile, boys 4.2 (47) 
Birth weight < 10th centile, girls 5.3 (59) 
Neonatal acidosis (pH < 7.2) 7.3 (82) 
Apgar score < 7 @ 1 minute 3.0 (34) 
Apgar score < 7 @ 5 minutes 0.3 (3) 
Suspected neonatal sepsis 3.7 (42) 
Admission to neonatal intensive care 5.9 (67) 
Table 3.4: Neonatal outcomes (percentage and number of cases) in 1119 singleton 
deliveries 
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3.4.3 Placental macroscopic findings 
 
1082 placentas had sufficient attached cord (≥ 15cm) to allow calculation of the cord 
coiling index (number of complete turns/cm). The mean cord length of these 1082 
placentas was 43cm (SD=13) and the mean cord coiling index 0.20 (SD=0.09). 
 
43 placentas (3.8% of the cohort) had macroscopically visible infarcts, as represented in 
Figure 3.1. 
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Figure 3.1. Frequency histogram detailing number of infarcts/case
in 43 cases of macroscopically identified infarction
 
 
 
 
A further 12 cases of infarction were recognised on histological examination. In total, 
therefore, 55 cases (4.9% of the cohort) of placental infarction, whether macroscopically or 
microscopically identified, were diagnosed. 
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3.4.4 Placental microscopic findings 
 
The histological reporting of the 1119 delivered placentas took place over two rounds, as 
described in Chapter 2. Initially, cases were categorized as per currently recognized 
reporting protocols. In particular, low-grade inflammatory lesions were disregarded. This 
allowed initial analysis of clinical outcomes in relation to current histological reporting 
protocols (15, 149) 
 
For this study, the objective was to identify all possible placental histological variants, 
whether previously considered to be pathological or not, in order to define specific 
histological subgroups and relate them to clinical outcomes. Further analysis of the 
subgroups identified by dropping the reporting threshold to any possible lesion, rather than 
any lesion considered to be significant in the context of current clinical practice, added a 
further 128 cases with potentially abnormal histology. The single largest category (67 
cases) was low-grade acute inflammatory change, with additional cases represented by 
low-grade villitis of unknown etiology (23 cases) and various inflammatory lesions of 
uncertain pathological significance (subacute chorionitis, plasma cell deciduitis, 
eosinophilic vasculitis) (24 cases). 
  
      
 Page |  49 
 
Histological diagnosis Percent (number of cases ) 
no significant histological abnormality. 71 (792) 
features of ascending genital tract infection. 11 (121) 
features of chronic placental underperfusion, 
including pre-eclampsia * 
7.1 (79) 
villitis of unknown etiology 3.7 (41) 
fetal thrombotic vasculopathy * 0.98 (11) 
features of acute abruption * 0.09 (1) 
chronic histiocytic intervillositis 0.27 (3) 
massive perivillous fibrin deposition * 0.45 (5) 
intervillous thrombus * 4.7 (53) 
chorangiosis 0.80 (9) 
chorangioma * 0.36 (4) 
Table 3.5 First round of histological reporting (50% FAJ, 50% NJS) 
* Sampling protocols were drawn up to ensure that lesions which rely on correlation with 
the placental macroscopic findings were reliably and representatively sampled for 
histological assessment, please see Appendix 4. 
 
 
Histological diagnosis Percent (Number of cases ) 
no significant histological abnormality. 58 (664) 
features of ascending genital tract infection. 17 (188) 
features of chronic placental underperfusion, 
including pre-eclampsia  
7.3 (82) 
villitis of unknown etiology 5.7 (64) 
fetal thrombotic vasculopathy  1.2 (13) 
features of acute abruption  0.80 (9) 
chronic histiocytic intervillositis 0.27 (3) 
massive perivillous fibrin deposition  0.71 (8) 
intervillous thrombus  4.7 (53) 
chorangiosis 0.80 (9) 
chorangioma  0.18 (2) 
plasma cell deciduitis 0.54 (6) 
eosinophilic inflammation  0.62 (7) 
subacute chorionic plate inflammation 0.98 (11) 
Table 3.6: Second round of histological reporting (all normal from 1
st
 round of reporting, 
FAJ) 
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Micro-anatomical location of 
inflammation 
Number of cases 
free membranes only 12 
mixed chorionic plate/free membranes 16 
chorionic plate  28 
subchorionic fibrin 68 
umbilical cord 64 
Table 3.7: Subclassification of cases showing histological features of ascending infection 
(n= 188) 
 
 
Number of inflamed umbilical cord 
vessels 
Number of cases 
1 48 
2 9 
3 7 
Table 3.8: Subclassification of funisitis (n=64) 
 
 
Variant of VUE Number of cases 
focal low-grade VUE 23 
multifocal low-grade VUE 21 
patchy high-grade VUE 11 
diffuse high-grade VUE 9 
Table 3.9: Subclassification of cases showing villitis of unknown etiology (n=64) 
 
3.5 DISCUSSION 
 
Clinical Outcomes 
 
Studies detailing clinical outcomes in unselected low-risk populations delivering at term 
are relatively rare within the literature. When compared with available statistics for the 
more commonly reported outcomes in low-risk deliveries in England (150, 151) and 
studies published in Switzerland (152) and Canada (153), the rates of obstetric and 
neonatal events in the present Cambridge study fall into the range of these previously 
published studies (see Table 3.10). There is clearly a degree of variation, some of which 
may be attributable to differences within populations and clinical management regimes.  
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Study 
 (reference) 
Study 
Period 
No of 
subjects 
Interventional 
deliveries (%) 
Apgar 
score < 7 
@ 1 
minute 
(%) 
Apgar 
score < 
7 @ 5 
minutes 
(%) 
Neonatal 
acidosis 
(5) 
NHS 
Hospital 
Episode 
Statistics 
(150) 
2010 -
2011 
668195 26  
_ 
 
_ 
 
_ 
Birthplace in 
England 
(151) 
2008-
2010 
64538 15 _ _ _ 
Switzerland 
(152) 
2000- 
2001 
3395 23 _ 
 
3 10.2 
Canada (153) 1998 – 
1999 
1314 22 13.5 0.9 _ 
Cambridge 2007 – 
2008 
1119 23 3 0.3 7.3 
Table 3.10: Clinical outcomes in comparable studies 
 
 
Birthweights for completed gestational weeks in the study cohort are given in comparison 
to United Kingdom national statistics (150) in table 3.11 
 
 
Completed 
gestational 
weeks 
Cambridge 
cohort mean 
weight (g) 
National cohort 
mean weight 
(g) 
36 2760 2712 
37 3001 2956 
38 3286 3180 
39 3515 3340 
40 3541 3483 
41 3702 3630 
42 3951 3710 
Table 3.11: Birthweights for completed gestational weeks, study cohort vs national cohort 
 
This study design also included a more extended range of clinical outcomes, with the 
objective of identifying all possible instances of suspected adverse outcome. The range of 
outcomes studied introduced occasional anomalies. A zero incidence of clinically 
suspected maternal chorioamnionitis was recorded. While this in part may be accounted for 
by the low-risk, predominantly term population studied, it is also apparent that in 
retrospect the clinical inclusion criteria for a diagnosis of clinical chorioamnionitis (two of 
maternal pyrexia, leucocytosis, offensive discharge or abdominal tenderness) may have 
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been overly rigid. Cases of suspected neonatal sepsis (infants with clinical history/findings 
sufficient to initiate blood cultures or antibiotic treatment) thus became the preferred 
indicator of infection, in this study, for correlation with acute inflammatory placental 
lesions. 
 
Macroscopic findings 
 
The mean and range of the cord coiling index in the study population in this project was 
similar to those reported for American (154) and Dutch (155) populations. Cord coiling 
indices in relation to clinical outcomes are considered in Chapter 4.  
 
Studies reporting rates of placental infarction in low-risk term placenta are, perhaps 
surprisingly, rare – extracting data from the published literature largely comes in the form 
of control groups taken from case control studies of small for gestational age infants. For 
the few studies of reportedly low-risk pregnancies delivering at term, the rates of placental 
infarction are as given in table 3.12. 
 
Study 
 (reference) 
Study Period No of subjects 
 
Cases of placental 
infarction (%) 
Becroft (20) 1995-1997 529 11.7 
Salafia (34) 2000 – 2001 179 10.1 
Stanculescu (156) 2008-2010 474 19.2 
Blair (33) 1980 – 1985 491 2.0 
Cambridge 2007-2008 1119 4.9 
Table 3.12: Comparison of rates of placental infarction amongst studies 
 
It is notable that the rates of placental infarction are quite variable amongst studies. The 
reasons are unclear. In the Cambridge study, macroscopically identified infarcts were all 
confirmed histologically, and additional cases were diagnosed histologically, giving little 
scope for systematic failure to recognize true infarction in the present series. The 
differences overall may relate both to true differences amongst populations rather than 
under-recognition in this study and differences in criteria for diagnosis of an infarct. 
 
Microscopic findings 
 
One of the principal questions of this study was to determine the clinical significance of all 
acute and chronic inflammatory lesions, particularly when analysed in subgroups, no 
matter how apparently insignificant the lesion appeared histologically. For this reason, 
rapid reporting of placental histological sections in line with current reporting protocols 
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was undertaken in the first instance, with a subsequent rescreen of all negatively reported 
slides in a second round of reporting. The inclusion in this study of all possible lesions, 
however minimal, does make comparison of the incidence of other inflammatory lesions in 
other studies difficult. 
 
For acute inflammatory changes, small numbers of studies exist, reporting variable levels 
of acute inflammation in term placentas, ranging from 10% to 17% in n=20 and n=661 
studies of high-risk deliveries (38, 157) to 35% in an n=195 study of low-risk deliveries 
(158). The definitions of histological chorioamnionitis in these studies are, however, 
variable, and are thus of limited value when attempting to extrapolate to different 
populations.  For this reason, in this study, previously proposed histological 
staging/grading systems for chorioamnionitis (36) were not considered to be useful. 
Microanatomical localization of acute inflammatory lesions was preferred in the present 
study, representing a descriptive, simplified approach to classification which could 
relatively easily be correlated with specific clinical outcomes. The Cambridge cohort study 
has thus generated very useful baseline data, describing the incidence of acute 
inflammation in low-risk term placentas, which is likely to serve as a reference point 
within the literature in this field. Chapter 6 describes the results of further sub-analysis and 
immunohistochemical characterization of the acute inflammatory lesions in this study. 
 
The rate of chronic villous inflammatory lesions – of any grade - in this study was 5.7%. 
When set against the rates in previously reported studies, this rate is comparable, as shown 
in Table 3.12 
 
Study 
 (reference) 
Study Period No of subjects 
 
Cases of VUE (%) 
Russell (159) 1976-1978 7505 7.6 
Knox (50) 1979 – 1980 1000 13.6 
Becroft (160) 1995 – 1997 529 11.7 
Vedmedovska (161) 2007 – 2008 50 6 
Cambridge 2007 – 2008 1119 5.7 
Table 3.13: Comparison of rates of villitis of unknown etiology (VUE) amongst studies 
 
These findings are further analysed, together with immunohistochemical characterisation, 
in Chapter 7. 
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3.6 CONCLUSIONS 
 
 
 1119 low-risk subjects recruited, delivering at or near to term. 
 Clinical outcomes and rates of potentially pathological placental lesions within the 
present study group compared to available data within the literature 
 In the Cambridge cohort: 
o Rate of over/undercoiling of umbilical cords approximately 20% 
o Rate of macroscopic placental infarction = 3.8%. An additional 1.1% of 
cases found to have infarction on microscopic examination. 
o Rate of acute histological placental inflammation (histological features of 
possible ascending genital tract infection): 11% when current routine 
histological  reporting protocols applied; 17% with all cases showing any 
evidence of acute histological inflammation included. 
o Rate of unexplained chronic placental parenchymal inflammation (chronic 
villitis of unknown etiology) =  3.7% when current routine histological  
reporting protocols were applied. Rate = 5.7% with all cases showing any 
evidence of chronic histological villous inflammation included. 
 These lesions (over/undercoiled umbilical cords, placental infarction, acute 
histological inflammation and chronic villous inflammation) selected for further 
sub-analysis and correlation with clinical outcome in later Chapters (4-7). 
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______________________________________________________ 
CHAPTER 4: UMBILICAL CORD OVERCOILING AND 
UNDERCOILING: CLINICAL OUTCOMES IN AN 
UNSELECTED POPULATION AND SYSTEMATIC REVIEW 
______________________________________________________ 
 
 
Summary: 
 
 Calculation of coiling index in placentas with umbilical cord length > 
15cm 
 Recording of five adverse neonatal outcomes in infants with umbilical 
cord length > 15cm. 
o Interventional delivery 
o Birthweight < 10th centile 
o Apgar score < 7 at one minute of age 
o Neonatal acidosis (pH < 7.2) 
o Admission to the neonatal intensive care unit 
 Systematic review 
o Study inclusion criteria 
o Literature search strategies 
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4.1 INTRODUCTION 
 
The human umbilical cord has an average length of around 50 cm, with approximately 11 
helical or spiral turns, parallel to the course of the vessels within. Assessment of the 
number of twists per unit length was defined in 1994 as the umbilical cord coiling index 
(17). While mechanical cord lesions (eg tight nuchal cord, cord prolapse, true cord knots) 
are incontrovertibly associated with adverse ante-partum or intra-partum events (162-164) 
there has been, for some time, considerable and ongoing interest within the literature in the 
relationship between the umbilical cord coiling index (derived both sonographically and 
following delivery) and clinical outcomes (154, 155, 165-171).  
 
Specific associations between variations in cord coiling outwith the presumed normal 
range and adverse perinatal events have been proposed in multiple studies over a number 
of years (18, 154, 155, 172, 173). The possible adverse outcomes identified are varied but 
very often those reported carry significant clinical implications: stillbirth, Apgar score < 7, 
intra-uterine growth restriction, fetal/neonatal acidosis and asphyxia. The topic remains 
controversial, with reservations expressed relating both to study design (174) and the likely 
clinical significance of reported positive associations (175). The mechanism(s) suspected 
of linking perceived abnormal umbilical cord coiling with adverse clinical outcomes are 
uncertain, but are commonly suggested to relate to fetal hypoxia, secondary to increased 
cord vulnerability to compression or kinking.  
 
4.2 METHODS 
 
This was an unselected prospective study, as discussed elsewhere. 1,082 delivered 
placentas had sufficiently long attached umbilical cords (>15 cm) to allow assessment of 
the coiling index. Placental examination was carried out either by FAJ or SP, with 
placental macroscopic examination carried out in accordance with previously published 
protocols (136, 176).  Coiling index was calculated as described by Strong (17).  
 
Markers of severely adverse clinical outcome in neonates include seizures, severe acidosis 
and death. For this study, in order to identify as many potentially adverse outcomes 
relating to variations in cord coiling index as possible a wider range of candidate adverse 
clinical outcomes were included – some were of a less severe nature, but still had the 
potential to identify fetuses/neonates with a degree of physiological compromise. These 
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clinical outcomes included interventional delivery,  birthweight < 10 centile, Apgar score < 
7 at 1 minute of age, neonatal acidosis (pH<7.2) and admission to the neonatal special care 
unit (previously reported in an initial cohort of 888 women with cord coiling studied in 
relation to placental shape) (24).  
 
A standardised systematic review model was employed to undertake the review. The 
review was constructed with specific criteria summarised in Table 4.1. Advanced searches 
of MEDLINE and EMBASE were undertaken over July 2011 to March 2012; search 
strategies are summarised in Table 4.2. Hand searching of relevant journals, searching of 
returned manuscript reference lists and direct email/postal approach to authors of 
conference abstracts was also undertaken. The process of selection is summarised in Figure 
2. Independent review of abstracts was undertaken by FAJ and Professor NJ Sebire, Great 
Ormond Street Hospital, London, with data extracted onto standardised forms: for each 
study, the minimum data required for inclusion of the study into the systematic review 
were:  clearly recorded numbers of participants with hypo-coiled (<10 centile), normally 
coiled (10
th
 – 90th centile) and hyper-coiled (>90th centile) umbilical cords plus the 
numbers of participants from each group experiencing at least one of the clinical outcomes 
as set out in Table 4.3. Statistical analysis was carried out by constructing forest plots of 
events occurring within individual studies expressed as odds ratios plotted on a log scale. 
Statistical heterogeneity was examined by comparison of the Chi
2 
value with the degrees of 
freedom (df). Risk of bias analysis and assessment of clinical heterogeneity was carried out 
as outlined in Cochrane review methodology (177).  
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types of study prospective cohort 
retrospective cohort 
 
participants pregnant women with ongoing singleton 
pregnancy > 16 weeks 
umbilical cord coiling index recorded by 
ultrasound or following delivery 
 
pathological event (exposure) umbilical cord coiling <10
th
 centile or > 
90
th
 centile 
 
outcome measure recorded Apgar score < 7 
interventional delivery 
neonatal acidosis 
fetal growth < 10
th
 centile 
 
Table 4.1: Criteria for considering studies for systematic review of umbilical cord coiling 
 
 
 
 
MEDLINE EMBASE 
longitudinal OR cohort OR follow-up OR 
prospective OR retrospective OR case 
control 
umbilical cord.mp or exp umbilical cord or 
umbilical artery.mp or exp umbilical artery or 
umbilical vein.mp or exp umbilical vein or 
umbilical vessel or exp umbilical vessel or 
AND AND 
umbilical cord [Title/abstract] OR 
umbilical vessel [Title/abstract] OR 
umbilical vascular [Title/abstract] OR 
umbilicus [Title/abstract] OR “umbilicus” 
[Mesh] OR “umbilical veins” [Mesh] OR 
“umbilical cord” [Mesh] OR “umbilical 
arteries” [Mesh] 
coil*.mp. or 
spiral*.mp. or 
twist*.mp. or 
helic*.mp. or 
helix.mp. 
AND AND 
(coil*) OR (spiral*) OR (twist*) OR 
(helix*) OR (helic*) 
exp cohort analysis/ or cohort.mp or 
exp retrospective study/ or retrospective.mp or 
prospective.mp. or exp prospective study or 
exp longitudinal study/ or longitudinal.mp. or 
exp case control study/ or case control.mp. 
 
Table 4.2: Search strategies for systematic review of umbilical cord coiling 
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4.3 STATISTICAL ANALYSIS 
 
Determination of mean values and standard deviations was carried out using standard 
Microsoft Excel software. RevMan software (142) was used to calculate odds ratios and 
the Chi
2
 statistic. GraphPad software (La Jolla, California, USA, www.graphpad.com) was 
used to create the frequency histograms, perform the subsequent analysis for normality 
with the D’Agostino and Pearson normality test. OpenEpi software (178) was used to 
determine p values from 2 x 2 table analysis, and also odds ratios with confidence 
intervals. Fisher’s exact test was preferred, given the small numbers of cases in some 
subgroups.  
 
4.4 RESULTS 
 
Cambridge cohort study 
 
1082 delivered placentas from the study population had sufficient attached umbilical cord 
for assessment of the umbilical coiling index.  Of this group, mean maternal age was 30.7 
years (SD=5.7) and 519 were primiparous. The mean cord length was 43cm (SD=13) and 
the mean cord coiling index 0.20 (SD=0.09), with a range of 0 to 0.55. Gaussian 
distribution of cord coiling in our cohort of 1082 was confirmed by the D’Agostino and 
Pearson normality test (K2 4.208, p value 0.1219) carried out on a frequency histogram 
(see Figure 4.1).  
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Figure 4.1. Frequency histogram of cord coiling index in 1082
cases with cords > 15cm.
 
 
Cases below the 10
th
 and above the 90th centiles were subsequently identified, with 108 
below the 10th centile (“hypo-coiled”), 866 between the 10th and 90th centile (“normally 
coiled”) and 108 above the 90th centile (“hyper-coiled”). The mean coiling index of the 
hypo-coiled group was 0.06 (SD=0.03) with a range of 0 to 0.10. The mean coiling index 
of the hyper-coiled group was 0.38 (SD=0.06) with a range from 0.32 to 0.55.  
 
No infants in this study presented with seizures and only two were found to have arterial 
blood pH < 7 at delivery, the latter group too small for meaningful statistical analysis. One 
death was recorded, a planned term delivery for anencephaly mapped onto a neonatal 
palliative care pathway. 
 
The number of events in each group for the four specific clinical outcomes included in this 
study are given in Table 4.3.  In view of the small numbers in some of the observed 
outcome groups, the data were analysed by creating 2x2 tables, with the outcome in either 
the <10th centile (hypo-coiled) group (n=108) or the >90th centile (hyper-coiled) group 
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(n=108) tested against the 10th-90th centile (n=866). Fisher’s exact test and the mid P 
exact test was applied to these data. Odds ratios, with mid P exact lower and upper 
confidence limits, were also calculated. The p values and odds ratios generated from this 
analysis are given in Tables 4.5 and 4.6. 
 
The mean birth weight and standard deviation for each of the three cord coiling groups 
were also calculated, and is summarized in Table 4.4. One way ANOVA testing was 
carried out, with the analysis given in Figure 4.2. This analysis shows equivocal variance 
amongst the groups, with a p value of 0.0446 showing significance not upheld by Bartlett’s 
test for equal variances. 
 
 hypo-coiled n=108 
<10th centile 
hyper-coiled 
n=108 
> 90th centile 
normal n=866 
10 – 90th centile 
Apgar < 7 @ 1min  
4 
 
3 
 
27 
interventional 
delivery (assisted 
vaginal/EMLSCS) 
 
 
24 
 
 
17 
 
 
211 
birth weight < 10
th
 
centile 
 
 
10 
 
 
15 
 
 
75 
admission to 
NICU 
 
 
5 
 
 
5 
 
 
56 
neonatal acidosis 
(arterial pH <7.2) 
 
 
7 
 
 
9 
 
 
63 
 
Table 4.3: Clinical outcomes in 1082 cases with > 15cm umbilical cord, stratified into 
hypo-coiled, hyper-coiled and normally coiled groups.  
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 hypo-coiled N=108 hyper-coiled 
N=108 
normal N=866 
mean birth weight 
(g) [SD] 
 
3492 [478] 
 
3371 [511] 
 
3499 [505] 
mean cord length 
(cm) [SD] 
 
40 [13] 
 
40 [15] 
 
43 [13] 
 
Table 4.4 : Mean birth weights and umbilical cord lengths in in 1082 cases with > 15cm 
umbilical cord, stratified into hypo-coiled, hyper-coiled and normally coiled groups. 
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Figure 4.2. Analysis of birth weight variance amongst cord coiling groups:
<10th centile, 10th -90th centile and >90th centile.
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 Fisher’s exact test 
(2-tail) 
mid P exact test  
(2-tail) 
odds ratio (95% 
confidence 
interval, mid P 
exact) 
Apgar < 7 @ 1min 
 
 
0.91 0.71 1.20 (0.35,3.25) 
interventional 
delivery (assisted 
vaginal/EMLSCS) 
0.72 0.63 0.88 (0.54,1.45) 
BW< 10
th
 centile 
 
 
0.94 0.81 1.08 (0.51,2.09) 
admission to NICU 
 
 
0.62 0.48 0.70 (0.24,1.68) 
neonatal acidosis  
(arterial pH <7.2) 
 
0.95 0.80 0.88 (0.36,1.90) 
 
Table 4.5: Statistical analysis of clinical outcomes, hypo-coiled cords (n=108) vs normally 
coiled cords (n=866) 
 
 
 
 
 Fisher’s exact test 
(2-tail) 
mid P exact test  
(2-tail) 
odds ratio (95% 
confidence 
interval, mid P 
exact) 
Apgar < 7 @ 1min 
 
 
>0.99 0.90 0.89 (0.21,2.7) 
interventional 
delivery (assisted 
vaginal/EMLSCS) 
0.05 0.04 0.58 (0.33,0.98) 
BW< 10
th
 centile 
 
 
0.06 0.04 1.7 (0.91,3.03) 
admission to NICU 
 
 
0.62 0.48 0.70 (0.24,1.68) 
neonatal acidosis  
(arterial pH <7.2) 
 
0.40 0.33 1.16 (0.53,1.68) 
 
Table 4.6: Statistical analysis of clinical outcomes, hyper-coiled cords (n=108) vs 
normally coiled cords (n=866) 
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Systematic review 
 
Six published studies were included in the systematic review, together with the current 
cohort, with the process of selection summarized in Figure 4.3. The characteristics of the 
included studies are given in Table 4.7. No studies providing specific data relating to 
admission to neonatal intensive care were identified and so this outcome was not studied 
further in the context of systematic review.  
 
study name 
(reference) 
antepartum/ 
postpartum 
study type cohort year number of 
subjects 
Predanic 
(179) 
antepartum prospective 2003 294 
Kashanian 
(170) 
postpartum prospective 2003-2004 699 
Rana (171) postpartum prospective 
cohort 
1994 508 
de Laat 2006a 
(155)  
postpartum prospective 
cohort 
2002-2003 885 
de Laat 2007 
(173) 
postpartum retrospective 
cohort 
1998-2002 565 
Chitra (180) postpartum prospective 
cohort 
nk 1000 
Cambridge postpartum prospective 
cohort 
2007-2008 1082 
 
Table 4.7: Characteristics of studies included in systematic review of clinical outcomes in 
cord coiling index variation. 
 
Statistical heterogeneity – assessed by comparing the Chi2 statistic with degrees of 
freedom, see Figures 4.4 to 4.11 – was striking, particularly in the analyses of hypo-coiling 
and hyper-coiling in relation to neonatal Apgar score <7 and interventional delivery.  
Overall, the Chi
2
 statistic was less than degrees of freedom in only one group for each 
analysis of hyper- and hypo-coiled cords.  
 
Clinical heterogeneity of studies was also judged to be high, with studies originating from 
the United Kingdom, the Unites States, the Netherlands, India and Iran and thus likely to 
include different baseline populations with different health care systems. Notably, the 
study closest in design to the Cambridge cohort study – that of Chitra et al – is likely to 
have been carried out on a substantially different clinical group: the results reported by 
Chitra et al include a low birth weight rate approaching 25%, substantially different to the 
Cambridge cohort rate of just under 10%.  The number of low birth weight infants in the 
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Chitra cohort may also have confounded the recording of Apgar scores, which are more 
likely to be low in low birth weight infants (181). 
Figure 4.3: Outcomes of literature searches carried out for umbilical cord coiling 
systematic review. 
Studies retrieved for hard copy review. 
n= 27 
Excluded studies (following 
title/abstract review) 
n= 70 
Potentially relevant citations identified from: 
Embase (1980 to 2012 Week 10) 34 
Pubmed 63 
Studies included in systematic 
review 
n= 6 
Excluded studies (following 
hard copy review) 
n= 21 
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For all studies included in the systematic review, including our own data, descriptive risk 
of bias analysis was carried out. The risk of reporting bias (unpublished negative data) in 
this systematic review is unknown, given that, to date, the cord coiling studies available in 
the literature report at least some positive findings. For all included studies, the risk of bias 
from attrition (variations in withdrawal from the study between groups) and detection 
(issues related to blinding of researchers) was judged to be low. For the studies by de Laat 
et al (155, 173), the risk of selection bias was high, with a population pre-selected for 
placental histological examination on clinical grounds and therefore likely to be high-risk 
with adverse outcomes. The risk of performance bias (variations in clinical care) was 
unclear, given the variations within intra-partum care across different countries (182). 
There was also high-risk of selection bias in the population included in the study by Rana 
et al (171), given that recruitment occurred in a high-risk perinatal centre. The risk of 
performance bias in this study was low. The risk of bias (selection and performance) 
within the Kashanian (170) and Chitra (180) studies was judged to be unclear. The 
Predanic (179) study had an unclear risk of bias for selection, given that 294 out of a 
baseline population of 425 met the study inclusion criteria of adequate ultrasound images 
and clinical history. The Cambridge cohort had an unclear risk of bias for selection: 
recruitment to this study favoured women with an uncomplicated ongoing pregnancy. The 
risk of performance bias was low.  
 
The results of analysis of heterogeneity (statistical and clinical) and risk of bias led to the 
conclusion that it presenting pooled quantitative data from the data currently available 
within the literature was not justified, nor calculation of odds ratios for the nominated 
outcomes. Forest plots are thus presented, in Figures 4.4 – 4.11, without pooled data icons. 
Analysis of findings in the forest plot format showed the data from the present study 
crossing the line of no effect for every outcome analysed. For a number of the other 
included studies – all of which reported findings as showing significant associations 
between variations in cord coiling and adverse outcomes – reanalysis of the published 
study data showed, for a number of outcomes, crossing of the line of no effect. 
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reporting small for gestational age infants as an outcome measure.
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cords reporting Apgar score <7 as an outcome measure.
line
 of
 no
 ef
fec
t
 
      
 Page |  68 
0.
1 1 10
Cambridge 2012
de Laat 2007
de Laat 2006a
favours normal coiling  favours hypo-coiling
Odds ratio, M-H, fixed, 95% CI
Heterogeneity: Chi
2
=0.43, df=2 (P=0.88)
Figure 4.6. Forest plot of studies of hypo-coiled umbilical
cords reporting neonatal acidosis as an outcome measure.
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cords reporting interventional delivery as an outcome measure.
line
 of
 no
 ef
fec
t
 
      
 Page |  69 
 
0.
01 0.
1 1 10 10
0
Cambridge 2012
Chitra 2012
de Laat 2006a
Kashanian 2006
Predanic 2005
Rana 1995
favours normal coiling favours hyper-coiling
Odds ratio, M-H, fixed, 95% CI
Heterogeneity: Chi
2
= 24.71, df=5 (P=0.0002)
lin
e o
f n
o e
ffe
ct
Figure 4.9. Forest plot of studies of hyper-coiled umbilical
cords reporting Apgar score <7 as an outcome measure.
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Figure 4.8. Forest plot of studies of hyper-coiled umbilical cords
reporting small for gestational age infants as an outcome measure.
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Figure 4.10. Forest plot of studies of hyper-coiled
umbilical cords reporting neonatal acidosis as an outcome
measure.
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4.5 DISCUSSION 
 
No statistically significant association between hypo-coiled or hyper-coiled umbilical 
cords and a number of adverse neonatal outcomes has been demonstrated in this study. For 
hyper-coiled cords compared to normally coiled cords, a p value of 0.04 was found for two 
groups, namely interventional delivery and birth weight less than 10
th
 centile. In a study of 
this size, these findings should be viewed as non-significant. No other p values <0.05 were 
demonstrated. 
 
The results of the Cambridge cohort are strikingly at variance with a number of studies 
previously reported within the literature (154, 155, 166, 170, 171, 173, 179, 180),  despite 
cord coiling indices determined for the our hypo-coiled and hyper-coiled groups falling 
into ranges similar to those published for other populations (154, 155).  
 
Consideration of the underlying reasons for this difference is an important question, 
particularly as cord coiling <10
th
 centile or > 90
th
 centile may be offered by placental 
pathologists as an explanation for adverse perinatal outcome and obstetricians are 
encouraged to consider how they might best determine and interpret the umbilical coiling 
index by ultrasound examination during pregnancy (168, 180, 183). 
 
As broad a range of clinical outcomes as possible was included, by noting both absolute 
values (low birth weight, fetal acidosis and Apgar score <7) and clinical parameters which 
would indicate that the medical teams caring for the mother and infant had identified 
clinical factors which gave cause for concern.   
 
Assessment of the Apgar score at delivery continues to be extremely valuable in predicting 
neonatal outcome, with scores ≥ 7 recognised as conferring a markedly reduced risk of 
neonatal death.  The interpretation of neonatal pH, although a very commonly used 
measure of neonatal well-being, particularly immediately after birth, is complex (148). 
Many research studies rely on a pH ≤ 7.0 as a cut-off for identifying cases of severe 
acidosis. In our cohort, we raised the level to pH ≤ 7.2, a level used to identify cases of 
milder acidosis, to avoid excluding less severe but potentially significant acidosis 
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associated with variations in the cord coiling index. Birthweight < 10th centile was defined 
by standard United Kingdom 4 - in - 1 growth charts(184). 
 
A decision to deliver a woman by interventional delivery is taken by the clinical obstetric 
team for a range of reasons: some maternal and some fetal. The decision thus relies on a 
broader assessment of intra-partum events than fetal tococardiography alone. It has been 
used as such in a number of previous studies of the clinical associations of umbilical cord 
coiling out with the perceived range of normal.  Admission to the neonatal special care unit 
is again a variable which depends on clinical decision-making but reflects sufficient 
impairment in one or more neonatal organ systems as to require specialist care. This study 
benefits from consistent clinical guidelines applied within one centre and these clinical 
outcomes were thus included as potentially useful.  
 
The selected parameters in this study are therefore sufficiently wide ranging and robust as 
to have captured infants who had any degree of compromise present at birth. Why, then, do 
these results appear to be different when compared to a number of previously published 
studies? 
 
In order to at least partially address this question, a systematic review of previously 
published cord coiling studies was undertaken, with inclusion criteria as broad as the 
format could accommodate.  
 
A number of the studies included in the systematic review have previously reporting 
significant associations between hypo-coiled and hyper-coiled umbilical cords. Extraction 
of the data and re-analysis in the forest plot format did not, for a number of outcomes, 
show any evidence of a significant effect. 
 
Overall, considerable statistical and clinical heterogeneity was found, together with high 
risks of bias when included studies were considered in the setting of the Cochrane review 
model. The systematic review model did not, therefore, support definite conclusions in 
favour of abnormal cord coiling as an abnormality associated with the perinatal outcomes 
studied. 
 
The strength of the Cambridge cohort study lies in the unselected nature and size of the 
cohort with selection of a small number of clinical outcomes of real relevance to the 
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wellbeing of the neonate: some of the variability reported amongst the previously 
published studies may be associated with the large number of outcomes studied. Further 
studies carried out on unselected prospective cohorts with clearly defined, important 
clinical outcomes, are likely to clarify the mixed messages now in existence relating to this 
area of placental study. 
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4.6 CONCLUSIONS 
 
 
 
 1082 cases with umbilical cords > 15cm were identified in the cohort of 1119. 
 The cord coiling indices calculated for these 1082 cases in this study are similar to 
those published for other populations 
 Five specific neonatal outcomes in infants were recorded: 
o Interventional delivery (252/1082) 
o Birthweight < 10th centiles (100/1082) 
o Apgar score < 7 at one minute of age (34/1082) 
o Neonatal acidosis (pH < 7.2) (79/1082) 
o Admission to the neonatal intensive care unit (66/1082) 
 No statistically significant associations relating adverse outcomes to cords below 
the 10
th
 centile were found. 
 No statistically significant associations relating adverse outcomes to cords above 
the 90
th
 centile were found. 
 Systematic review of the literature identified six studies fulfilling the criteria for 
inclusion 
 The data from a number of included studies was shown, in the forest plot format, to 
cross the line of no effect. 
 Heterogeneity analysis (both statistical and clinical), together with risk of bias 
assessment, indicated that generating pooled quantitative data with generation of 
odds ratios could not be justified. 
 There is no evidence, either from the data generated in this study or from a 
systematic review, to support the conclusion that variations in umbilical cord 
coiling indices are associated with adverse neonatal outcomes. 
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______________________________________________________ 
CHAPTER 5: CLINICAL CORRELATION OF 
MACROSCOPIC AND MICROSCOPIC PLACENTAL 
INFARCTION IN AN UNSELECTED POPULATION, WITH 
IMMUNHISTOCHEMICAL ANALYSIS 
______________________________________________________ 
 
 
Summary: 
 
 
 Placental perfusion  
 Assessment of fetal and placental growth: raw data and z scores 
 Variations in cord insertion site and placental shape 
 Identification of placental infarcts: macroscopic and microscopic 
 Relationships between placental infarcts, maternal hypertension, 
fetal/placental growth and variations in cord insertion site or placental 
shape 
 Pilot immunohistochemical studies 
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5.1 INTRODUCTION 
 
The underlying event in infarction of biological tissues is, in most organ systems, 
attributable to occlusion of the local arterial blood supply. This is self-evident for very 
common lesions in other tissues – typically infarction of the myocardium secondary to 
coronary artery occlusion – but is more complex for the human placenta, which receives a 
dual blood supply from the left and right uterine arteries. The chorionic villi are 
vascularised by branching of fetal vessels, but are also in direct contact with the maternal 
blood in the intervillous space. There is little evidence in the more recent literature for the 
view that the fetal vasculature is primarily compromised in the pathogenesis of placental 
infarction, and studies of placental perfusion suggest that, although the micro-architecture 
of the placenta may be suggestive of a freely communicating intervillous lake of maternal 
blood, functional studies are much more in keeping with maternal spiral arteries 
functioning as end arteries (3). Presumed occlusive events within these end arteries, either 
within the more superficial maternal decidua which separates from the placental bed at 
parturition or (probably more commonly) within the deeper maternal spiral arteries, results 
in placental parenchymal infarction (34, 83, 122). A schematic depiction of human 
placental micro-circulation is given in Figure 5.1 (after L’Herminé-Coulomb) (185).  
 
 
 
Figure 5.1: human placental micro-circulation 
 
Second and third trimester growth and later development of the placenta (and fetus) are 
dependent on appropriate transformation of maternal uterine arteries, mediated by 
chorionic plate vessels 
intervillous space 
fetal arteriole 
fetal 
venule 
maternal blood flow 
trophoblast 
 
 fetal blood 
flow maternal blood 
flow 
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trophoblast invasion of these vessels. Deficiencies in trophoblast invasion are linked to 
placental oxidative stress, placental infarction and fetal growth restriction (186, 187).  This 
pathway has thus received considerable attention in the setting of preterm, small for 
gestational age infants (90).  The clinical outcomes and thus significance of term placental 
infarction are less certain: placental infarction is considered in multiple clinical studies to 
be associated with small for gestational age infants at term (20, 27, 29, 34, 131, 161, 188, 
189), but few unselected cohort studies of outcomes in placental infarction at term have 
previously been reported (20, 34).  
 
The relative importance of recording and analysing birth weight alone, placental weight 
alone or a combined birth:placental weight ratio remains controversial: fetal and placental 
weight have been reported to be strongly correlated (190, 191) and a number of studies 
report that variations in birth:placental weight ratios are associated with adverse outcomes 
(188, 192, 193). This analysis has, however, been criticised in that a “normal” 
birth:placental weight is calculated when both birth and placental weight are normal, low 
or high (194), and z scores have been advocated as a more robust form of analysis in the 
investigation of fetal and placental growth (138, 194).  
 
The specific mechanisms of disease which cause arterial lesions in placental infarction are 
not well understood. A proportion of placental infarcts are consistently associated with 
specific maternal pathology: hypertensive disorders (30, 44, 195-197), factor V Leiden 
deficiency (198), antiphospholid syndromes (199)  and other maternal connective tissue 
disorders (200). The remainder of recognised placental infarcts are idiopathic.  
 
Macroscopic variations in umbilical cord insertion (201, 202) and placental disc shape 
(203) have been advanced as an explanation for placental “insufficiency” and a wide range 
of abnormal pathways in cell biology have been investigated to account for apparent 
placental hypoxia (186, 204-207), although the majority of studies in this field are 
predominantly directed towards investigating growth in the context of pre-eclampsia. 
 
In this study, the relationships between placental infarction and both fetal and placental 
growth are investigated in some detail, with growth analysed both as raw data and as z 
scores. Quantification of infarcts against fetal and placental growth is also reported.  
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Possible pathways accounting for placental infarction are investigated at multiple levels: 
clinical, macroscopic and microscopic. The relationship between maternal hypertensive 
disorders and placental infarction in this cohort is examined. At the macroscopic level, 
variations in umbilical cord insertion site and placental eccentricity in the presence or 
absence of infarcts are investigated. Finally, the analysis of pilot immunohistochemical 
studies of possible cell biology pathways implicated in the pathogenesis of placental 
infarction is reported. 
5.2 METHODS 
 
Macroscopic and microscopic analysis of placentas, photography and neonatal data 
collection were carried out as described in Chapter 2, section 2.2.3. 
 
ImageJ software was used to calculate both the percentage infarction of the cut surface of 
placentas with macroscopically recognised infarction, and to calculate the area of villi in 
each case analysed immunohistochemically, again as described in Chapter 2, sections 2.2.5 
and 2.2.11. For antigens identifying individual cells (eg CD3), total positive cell counts 
were recorded. For cell surface expression of antigen, each positive villus was recorded. 
 
Calculation of indices expressing variations in cord insertion and placental disc 
eccentricity have previously been reported (24): briefly, the cord centrality index is 
expressed as a value between 0 and 1. The smaller the cord centrality index, the closer to 
the centre lies the cord insertion site and, conversely, the larger the cord centrality index, 
the further away from the centre it lies. Eccentricity index is expressed on the basis of a 
mathematical formula which expresses a perfect circle as a value of 0 with a maximally 
elliptical shape as a value of 1. 
5.3 STATISTICAL ANALYSIS 
 
Noting the discussion above relating to the relative importance of birth weight, placental 
weight and birth:placental weight ratio, multiple analyses were undertaken, The initial 
analysis performed was that an uncorrected comparison of infarct to non-infarct cases by 
birth weight, placental weight and birth:placental weight ratio. Subsequently, calculation of 
z scores, which assess the deviation from the mean for each value analysed, was carried out 
on a gestational age (completed gestational week) specific basis. 
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Statistical testing was undertaken with OpenEpi (178)  and GraphPad (146) software, with 
generation of t test and Spearman rank correlation co-efficient p values. 
5.4 RESULTS 
 
All cases of placental infarction occurred in cases of 37-42 weeks gestation, and the 
control group was thus restricted to cases from the same gestational age group. Infarcts 
were identified in a total of 55 (5.1%) cases – 43 (4.0%) cases had a macroscopically 
identifiable infarct (subsequently confirmed histologically), with a further 12 (1.1%) of 
cases noted to have parenchymal infarction on microscopic examination of cases with no 
observed macroscopic abnormalities. For the 43 cases with a macroscopically recognised 
infarct, further analysis of the number of recognisable infarcts and the percentage of 
recognisably infarcted placental parenchyma was undertaken. These data are presented in 
Table 5.2. Twenty nine macroscopically recognised cases of infarction included only one 
or two infarcts, with fourteen cases including three or more: the mean number of 
infarcts/case was 2.44 (SD 2.71) and the mean percentage infarction/case was 1.36% (SD 
2.09). 
 
As noted, all 55 cases of infarction fell into the gestational age range 37-42 weeks. Only  
one case was >41 weeks and so infarct cases were stratified into 37, 38, 39, 40 and 41+ 
completed gestational weeks.  This gestational age range was applied to the control (non-
infarct) group which, with the exclusion of cases of gestation < 37 weeks and > 42 weeks, 
numbered 1025. There was no statistical significance between the number of cases for each 
completed gestational week for infarcts compared to non-infarcts (see Table 5.1 and Figure 
5.2).  
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Figure 5.2: infarcted placentas vs non-infarcted placentas by
gestational week
 
 
 
 Infarct (%) 
n=55 
Non-infarct (%) 
n=1025 
 
p value 
37 weeks 4 (7) 55 (5) 0.71 
38 weeks 5 (9) 136 (13) 0.51 
39 weeks 15 (25) 271 (26) 1.0 
40 weeks 19 (34) 287 (28) 0.36 
41 + weeks 13 (24) 276 (27) 0.72 
Table 5.1: Infarcted placentas vs non-infarcted placentas by gestational week 
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NO. OF 
INFARCTS 
% 
INFARCT 
CUT 
SURFACE 
AREA 
(cm2) 
INFARCT 
SURFACE 
AREA 
(cm2) 
1 0.74 270 2.0 
1 0.37 207 0.76 
1 0.27 175 0.47 
1 0.71 240 1.7 
1 0.21 238 0.5 
1 0.47 236 1.1 
1 0.31 180 0.56 
1 0.16 209 0.34 
1 0.21 221 0.47 
1 0.60 218 1.3 
1 0.48 158 0.76 
1 0.65 262 1.7 
1 0.88 159 1.4 
1 0.47 224 1.0 
1 0.30 265 0.8 
1 0.64 234 1.5 
1 0.74 162 1.2 
1 0.08 130 0.1 
1 0.21 191 0.4 
1 0.79 266 2.1 
1 0.79 189 1.5 
1 0.40 170 0.68 
2 1.4 189 2.6 
2 1.6 165 2.7 
2 2.7 265 7.1 
2 1.3 176 2.3 
2 0.35 173 0.6 
2 2.2 169 3.7 
2 0.74 270 2.0 
3 0.59 158 0.93 
3 5.0 242 12 
3 0.90 265 2.4 
3 0.85 223 1.9 
3 0.80 201 1.6 
3 1.3 202 2.6 
4 1.1 160 1.8 
4 3.4 160 5.4 
4 3.2 169 5.4 
4 0.75 173 1.3 
6 3.2 278 9.0 
6 2.1 165 3.4 
6 1.5 177 2.6 
17 13 138 18 
Table  5.2: Analysis of macroscopically recognisable placental infarcts 
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Birthweight and placental weight analyses 
 
Calculation of p values for birthweight, placental weight and birth:placental weight ratio 
for infarcted and non-infarcted placentas showed statistically significant differences for 
birthweight but not for placental weight or birth:placental weight. These findings are 
presented graphically in Figures 5.3-5.5. 
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Figure 5.3 Birthweight, infarcts vs controls
(uncorrected for gestational age, 37 - 42 weeks)
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Figure 5.4. Placental weight, infarcts vs controls
(uncorrected for gestational age, 37 - 42 weeks)
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Figure 5.5. Birthweight:placental weight ratio,
infarcts vs controls
(uncorrected for gestational age, 37 -42 weeks)
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The relationships between percentage infarction and birth weight, placental weight and 
birthweight:placental weight were also examined. There was no statistical correlation 
between percentage of placental infarction and any of these variables in this study. These 
data are presented in Figure 5.6. 
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Figure 5.6. Scatterplot of birthweight, placental weight and birthweight:placental
weight ratio vs % placental infarction
w
e
ig
h
ts
/w
e
ig
h
t 
ra
ti
o
s
 (
lo
g
 s
c
a
le
)
 
 
 
 
 
 
 
 
 
 
 
      
 Page |  85 
 
The significant p value for birthweight when comparing infarcts and non-infarcts noted, 
the gestation specific z scores were compared for birth weight, placental weight and 
birthweight:placental weight. These showed no significant differences for infarcts 
compared with non-infarcts for these three growth parameters. These findings are 
presented graphically in Figures 5.7 -5.9. Percentage infarction against z score birthweight 
is shown in Figure 5.10. This analysis was again statistically non-significant. 
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Figure 5.7. z scores (birth weight), infarcts vs controls
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Figure 5.8. z scores (placental weight), infarcts vs controls
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Figure 5.9. z scores (birthweight:placental weight), infarcts vs controls
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Figure 5.10. z score birth weight vs placental infarction (%)
p=0.70
 
 
 
Maternal hypertensive disorders and placental infarction 
 
Three subjects, out of the 55 found to have identifiable placental infarction, had a 
pregnancy-related hypertensive disorder. Given the low incidence, no further subdivision 
of hypertensive disorders was undertaken. Of the 1025 controls, 48 had a pregnancy-
related hypertensive disorder. 
 
As shown in Table 5.3, there was no significant difference between the incidence of 
hypertensive disorders of pregnancy in the infarct vs control groups. 
 
 Maternal 
hypertension 
Maternal 
normotension 
Totals 
Infarcts 3 52 55 
Non-infarcts 48 977 1025 
Totals 51 1029 1080 
p = 0.75 
Table 5.3. Two by two table, maternal hypertensive disorders vs placental infarction 
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Cord centrality/placental eccentricity and placental infarction 
Correlation of the cord centrality and eccentricity indices calculated elsewhere (24) with 
infarcts versus non-infarcts showed no significant correlation between cord centrality or 
placental eccentricity. These findings are presented in Figures 5.11 and 5.12. 
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Figure 5.11. Cord centrality index, infarcts vs controls
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Figure 5.12. Placental eccentricity index, infarcts vs controls
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Immunohistochemical studies 
 
Immunohistochemical staining and analysis was carried out on two sets of micro-arrays, 
placental tissue just adjacent to a focus of infarction and placental control tissue. Each 
microarray comprised 20 cases, with preparation and immunohistochemical staining as 
described in 2.2.9 and 2.2.10. The target cell type/antigen is given in Table 5.4. The results 
of scoring each micro-array are given in Figure 5.14. 
 
Primary antibody Cell type/antigen 
CD3 T cell 
CD20 B cell 
HLADR cell surface class ii major histocompatibility 
complex 
CD68 macrophage/monocyte series 
C4d complement activation 
cleaved caspase 3 (Cl-Cas3) apoptosis marker 
ICAM (CD54) leukocyte/endothelial transmembrane 
adhesion molecule  
P selectin (CD62P) activated endothelial/activated platelet 
transmembrane adhesion molecule  
Fox P3 T regulatory cell (TREG) phenotype 
Table 5.4. Immunohistochemical panel: target cell type/antigen  
 
Given that these were pilot studies, no statistical analysis was performed on These data. 
Initial results suggested that C4d and cleaved caspase 3 may be of further interest in 
definitive immunohistochemical studies. C4d decorated the syncytiotrophoblast of 
chorionic villi adjacent to infarction, while cleaved caspase 3 had a granular cytoplasmic 
staining pattern in villous stromal cells. 
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Figure 5.13 Immunohistochemical expression of C4d (left) and cleaved caspase 3 (right) 
adjacent to a focus of placental infarction ( x 10 objective). 
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CD3 0.00 0.00 20 3.76 2.93 20 
CD20 0.64 0.68 20 1.20 1.36 20 
CD54 1.75 6.92 20 14.80 34.20 20 
CD62p 1.48 2.51 20 1.86 2.49 20 
CD68 1.51 2.62 20 9.25 15.10 20 
C4d 9.90 14.10 20 3.76 13.80 20 
HLA-DR 1.18 1.25 20 2.22 3.18 20 
Cl-Cas3 28.70 41.90 20 24.30 34.60 20 
Fox- P3 0.00 0.00 20 0.00 0.00 20 
 
Figure 5.14. Immunohistochemical analysis, placental infarction vs control
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5.5 DISCUSSION 
 
Placental infarcts are macroscopically and microscopically recognisable lesions where the 
placental parenchyma has undergone necrosis – with, as noted above, most evidence 
supporting occlusion of maternal end arteries as the primary event. Most studies reporting 
outcomes in placental infarction focus on fetal growth/birth weight as the outcome 
endpoint, and this model was adopted in the present study. 
 
Very few studies exist which report on infarction in unselected cohorts delivering at term. 
The majority reporting a definite association between growth restriction and placental 
infarction are, as discussed in Chapter 3, case control studies, with an estimate of the true 
incidence within a population only available from an analysis of an individual study’s 
control group.  
 
This study reports a significant association between birthweight and infarction (in 
comparison to the non-infarcted cases in this cohort) only on analysis of the raw data. 
When standardised for gestational age, by calculation of the z score, this effect 
disappeared. The z score data are to be preferred in this context, as each value is expressed 
as a variation from the mean for each gestational week. Associations between the 
percentage infarction of each placenta in which macroscopic infarcts were identified and 
birthweight, placental weight and birthweight:placental weight were also explored: no 
association was shown in this study. There was no association between maternal 
hypertensive disorders and placental infarction in this study. 
 
Previous studies have reported only on raw data in a case control model, and two of the 
largest (20, 34) date from 2002 and 1992, respectively. There may thus be multiple factors 
which account for the differences between this study and those previously published. 
 
First, the case control model introduces a risk of bias. It is much more difficult to avoid 
selection bias in the non-random selection of cases: however conscientiously the researcher 
attempts to exclude bias, the case selection may be stratified for both abnormal and control 
groups. There is also, depending on the study design, the possibility that the researchers are 
not blinded when assessing the macroscopic and microscopic appearances of the placentas. 
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Secondly, obstetric management may have biased the findings in this study against the 
detection of all placental infarcts in the baseline population – intervention, by delivery of 
the infant on a semi-elective or emergency basis, may have resulted in diminished 
opportunities to recruit some cases of placental infarction, given that the design of the 
present study resulted in a bias towards recruitment of uncomplicated pregnancies 
delivering at term.  
 
Thirdly, the populations examined in the small number of studies reporting on term 
placental infarction may be quite variable, both in terms of ethnic origin and smoking (20) 
and maternal pre-conceptual body mass index (34). The Cambridge population, as noted in 
Chapter 3, was a predominantly low-risk Caucasian population. 
 
Nevertheless, the data that are available from this study support the conclusion that the 
incidence of maternal hypertension, birth weight, placental weight and birth:placental 
weight ratio, in pregnancies delivering between 37 and 42 weeks, show no evidence of 
variation between those cases showing placental infarction and those without. 
 
The cord centrality index and placental eccentricity index were examined for association 
with placental infarction. As demonstrated, there was no apparent association between the 
these variables and placental infarction. This study thus provides no evidence that placental 
infarction may be the underlying lesion in those clinical studies  reporting placental 
“insufficiency”, or reduced efficiency,  in the context of variable cord insertion and 
placental shape (16, 25, 201, 202). 
 
A further objective of this study was to evaluate possible immunohistochemical markers in 
the elucidation of pathways of placental infarction. A pilot study of immunohistochemical 
staining, with a range of markers, carried out on 20 cases of placental parenchyma adjacent 
to an infarct and 20 controls, identified C4d and cleaved caspase 3 as markers of interest 
for more definitive studies. 
 
The finding that C4d shows, in these pilot studies, an increase in staining in viable 
chorionic villi adjacent to areas of infarction is of interest given recent studies reporting 
activation of complement in placentas delivered by women diagnosed with hypertensive 
disorders of pregnancy, antiphospholipid syndrome or systemic lupus erythematosus (208, 
209). These studies describe statistically significant associations between C4d and disease 
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compared with normal controls, and conclude that activation is via the antibody mediated 
classical pathway.  In the present study, however, the presence of C4d expression adjacent 
to foci of placental infarction in low-risk pregnancies with no statistically significant 
adverse outcome raises the possibility that the presence of C4d is possibly a non-specific 
marker for complement activation via the lectin pathway, triggered by tissue damage. In 
this context, the observation that apoptotic placental tissue is observed to activate 
complement systems (43, 81, 82) is highly relevant: the suggestion that there may be a 
threshold effect to clinically significant apoptosis and complement activation (82) is 
attractive  and merits further evaluation in the context of low-risk, normal outcomes 
pregnancies with identifiable placental infarcts.  
 
Cleaved caspase 3 was also found to have increased expression in chorionic villi adjacent 
to placental infarcts compared to normal controls. In many ways, this finding has parallels 
with the findings for C4d expression in this study. Activation of placental apoptosis is 
reported to be associated with pre-eclampsia (210) and the caspases are certainly a family 
known to be highly involved in the intracellular apoptotic pathway (92). Again, 
investigation of the pattern of expression of a more extended set of apoptosis markers in 
low-risk, normal outcome pregnancies with identifiable placental infarcts is likely to 
provide clearer insights into the relationships between apoptosis and adverse outcome.  
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5.6 CONCLUSIONS 
 
 
 55 cases of placental infarction identified 
 No statistically significant difference in incidence of placental infarction by 
gestational week (37-42) compared with controls 
 No statistically significant difference in placental weight and birth:placental weight 
in analysis of raw data or z scores 
 Marginally statistically significant difference in birth weight on analysis of raw 
data, not sustained on z score analysis 
 No statistically significant correlation between percentage placental infarction and 
birth weight, placental weight or birthweight:placental weight 
 No statistically significant difference in incidence of infarcts in maternal 
hypertensive disorders compared to normotensive controls 
 No statistically significant correlation between infarcts and cord centrality index or 
placental eccentricity  
 Pilot immunohistochemical studies identify increased C4d and cleaved caspase 3 
(markers of complement activation and apoptosis) expression in chorionic villi 
adjacent to placental infarction compared to controls 
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______________________________________________________ 
 
CHAPTER 6: CLINICAL CORRELATION OF ACUTE 
PLACENTAL HISTOLOGIC INFLAMMATION PATTERNS 
IN AN UNSELECTED POPULATION 
______________________________________________________ 
 
 
Summary: 
 
 Cases showing any degree of acute inflammation identified 
o Cases classified as abnormal by current reporting protocols 
o Cases showing any degree of acute inflammation 
 Five specific neonatal outcomes identified 
o Interventional delivery 
o Birthweight  
o Apgar score < 7 at one minute of age 
o Neonatal acidosis (pH < 7.2) 
o Admission to the neonatal intensive care unit 
 Associations between acute inflammation and clinical outcomes 
examined 
 Fetal inflammatory response syndrome reviewed 
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6.1 INTRODUCTION 
 
Chorioamnionitis and funisitis are defined histologically as acute inflammatory responses 
in, respectively, the fetal membranes and umbilical cord. There is longstanding 
accumulated evidence that the observed acute inflammation is attributable to ascending 
genital tract infection.  The presence of inflammation in cord and membranes is reported to 
have considerable implications for both early and late well-being in pre-term neonates, 
with multiple major studies reporting adverse outcomes in clinical and histological 
chorioamnionitis (74-76, 106, 211-214). Interestingly, conflicting evidence exists for some 
clinical outcomes in pre-term chorioamnionitis -  for example, the lesion is reported to be 
both positively (106) and negatively (214) associated with pre-term intra-ventricular 
haemorrhage. The effects of chorioamnionitis on premature infant lung function also 
appear complex with apparently contradictory findings of decreased frequency of short -
term respiratory distress syndrome but increased frequency of long-term chronic lung 
disease/bronchopulmonary dysplasia. (215). Regardless of the specific positive or negative 
effects of chorioamnionitis, the pathway by far the most commonly cited as inducing a 
physiological effect on the pre-term infant is the fetal inflammatory response syndrome, 
mediated by interleukin 6 and thought likely to be of considerable importance in the setting 
of a leaky, immature blood brain barrier (216-218). 
 
For term deliveries, the significance of an acute histological inflammatory 
chorioamnionitis or funisitis is less clear. Publications describing clinical outcomes in term 
pregnancy are much less frequent, and predominantly explore associations between the 
development of chorioamnionitis and cerebral palsy (118). It has previously been reported, 
however, that there is no evidence of an association between relatively severe term 
neonatal acidosis and intra-uterine infection (219). A recent report raises the controversial 
hypothesis that term chorioamnionitis may not be infective in origin (158). 
 
Assessment of the significance of acute inflammation in placentas delivered from term 
pregnancy is, however, an important question – not least because, as guidelines for routine 
clinicopathological assessment of the placenta accumulate, the onus on the individual 
reporting pathologist is to recognise all possible pathologic lesions, while disregarding 
histological patterns of no or limited diagnostic significance.  Resolving these issues would 
also be of considerable interest to practising obstetricians and neonatologists in 
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determining which placentas to submit for histological examination and in understanding 
the significance of the resulting histopathology report.  
 
This study provides a rare opportunity to consider the clinical outcomes of acute 
inflammatory patterns in varying compartments of placental microanatomy, in the specific 
clinical setting of low-risk pregnancies delivering around term.  
 
6.2 METHODS 
 
Detailed accounts of recruitment to the study, recording of clinical data, microscopic and 
microscopic placental examination are given in Chapter 2. 
6.3 STATISTICAL ANALYSIS 
 
Birth weight amongst subgroups was, as a continuous variable, analysed by one way 
ANOVA testing.  
 
For clinical associations, which take the form of discrete variables, Fisher’s exact and mid 
P values were calculated, together with odds ratios and 95% confidence intervals. 
 
The statistical tests used are further discussed in Chapter 2. 
6.4 RESULTS 
 
As noted in Chapter 3, 188 cases out of the 1119 included in this study showed some 
degree of acute inflammation. Based on current clinical practice (3), 121 of these 188 
would have been reported as potentially significant by a routine diagnostic 
histopathologist: the remaining 67 were cases showing changes which were judged to be, 
on the first round of reporting, minor infiltrates of polymorphs of no diagnostic 
significance.  
 
The numbers of cases in each subgroup following a second round of light microscopy have 
been presented in Chapter 3: to reprise, Table 3.7 is reprinted below for ease of review as 
Table 6.1. 
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Micro-anatomical location of 
inflammation 
Number of cases 
free membranes only 12 
mixed chorionic plate/free membranes 16 
chorionic plate  28 
subchorionic fibrin 68 
umbilical cord 64 
Table 6.1  Subclassification of cases showing histological features of ascending infection 
(n= 188) 
 
6.4.1 Clinical outcomes 
 
A number of clinical outcomes, including birth weight, Apgar score at 1 minute of age, 
interventional delivery, suspected neonatal sepsis and admission to the neonatal intensive 
care unit, were investigated for each histological subgroup. All cases showing no evidence 
of chorioamnionitis, regardless of gestational age, formed the control group. 
 
For birth weight, one way analysis of variance (ANOVA) testing for birth weight showed 
no difference amongst the subgroups studied, as summarized in Table 6.2. 
 
 
Subtype No of cases Mean birth weight SD 
no chorioamnionitis 933 3468 508 
funisitis 64 3533 512 
subchorionic 
inflammation only 
68 3543 480 
combined chorionic 
plate, free 
membranes and 
subchorionic 
inflammation 
16 3721 521 
chorionic plate 
inflammation only 
28 3644 355 
free membrane 
inflammation only 
12 3408 465 
Test for equality of variance: Chi
2 
= 5.85, degrees of freedom (df) = 5, p value = 0.32. 
 
Table 6.2.Birth weight in acute inflammation – one way ANOVA 
 
 
The clinical outcomes for all cases of chorioamnionitis (present or absent) are shown in 
Figure 6.1 and table 6.3. 
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 Apgar score<7 
 
(% cases) 
Interventional 
delivery 
(% cases) 
NICU 
admission 
(% cases) 
Clinical sepsis  
 
(% cases) 
no 
chorioamnionitis 
(n=933) 
23 
(2.5) 
175 
(19) 
55 
(5.9) 
34 
(3.6) 
all 
chorioamnionitis 
(n=188) 
11 
(5.8) 
82 
(44) 
12 
(6.4) 
8 
(4.3) 
Table 6.3.Clinical outcomes in histological chorioamnionitis (all cases) 
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Figure 6.1. Clinical outcomes in
histological chorioamnionitis (CA)
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The subgroups of chorioamnionitis examined were as follows: 
 no chorioamnionitis (no CA) 
 funisitis 
 subchorionic fibrin inflammation (SCF inflammation) 
 inflammation of chorionic plate, free membranes and subchorionic fibrin (CP, 
membranes, SCF) 
 chorionic plate inflammation (CP only) 
 free membranes (membranes only) 
The clinical outcomes on analysis of chorioamnionitis are shown in Figure 6.2 and Table 
6.4. 
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 Apgar score<7 
 
(% cases) 
Interventional 
delivery 
(% cases) 
NICU 
admission 
(% cases) 
Clinical sepsis  
 
(% cases) 
no 
chorioamnionitis 
(n=933) 
 
 
23 
(2.5) 
175 
(19) 
55 
(5.9) 
34 
(3.6) 
funisitis (n=64) 
 
 
 
 
7 
(11) 
38 
(61) 
 
9 
(15) 
7 
(11) 
subchorionic 
fibrin (SCF) 
inflammation 
(n=68) 
 
 
1 
(1.5) 
25 
(37) 
2 
(2.9) 
0 
(0) 
chorionic plate 
(CP),membranes, 
subchorionic 
inflammation 
(n=16) 
1 
(6.2) 
8 
(50) 
0 
(0) 
0 
(0) 
chorionic plate 
inflammation 
only (n=28) 
 
1 
(3.6) 
8 
(2.8) 
0 
(0) 
0 
(0) 
membrane 
inflammation 
only  (n=12) 
 
1 
(8.3) 
3 
(25) 
1 
(8.3) 
1 
(8.3) 
Table 6.4.Clinical outcomes in chorioamnionitis (subgroups) 
 
 
The statistical analysis of the data presented in Figures 6.2 and 6.3 is given in Tables 6.3 – 
6.8, in which the clinical associations between all chorioamnionitis and the five subgroups 
are examined.  The control group was formed by the 933 cases showing no evidence of any 
acute inflammation. 
 
For all forms of chorioamnionitis – where the study population was divided into two 
groups, acute inflammation present and acute inflammation absent – there were significant 
associations between Apgar score <7 (p = 0.02, OR 2.48, CI 1.15-5.14) and interventional 
delivery (p <0.001, OR 3.41, CI 2.44 – 4.76).  
 
      
 Page |  102 
When the five subgroups, addressing the significance of acute inflammation in the 
anatomical compartments described, were analysed, there were no significant associations 
between acute inflammation in the chorionic plate alone, the free membranes alone or the 
subchorionic fibrin alone.  
 
Acute inflammation extending through the free membranes, chorionic plate and 
subchorionic fibrin was significantly associated with interventional delivery (p = 0.006, 
OR 4.3, CI 1.5 - 12.1). 
 
Funisitis was significantly associated with all four clinical outcomes (Apgar score < 7 at 1 
minute, interventional delivery, clinical evidence of sepsis and admission to the neonatal 
intensive care unit. The statistical analysis supporting these conclusions is given in Table 
6.4 
 
Clinical 
association 
Fisher’s exact 
(2-tail) 
Mid P exact 
(2-tail) 
Odds ratio and 
95% CI, mid P 
exact 
Apgar score <7 0.01 0.02 2.48 (1.15,5.14) 
interventional 
delivery 
<0.001 <0.001 3.41 (2.44,4.76) 
admission to 
NICU 
0.87 0.75 1.18 (0.51,2.53) 
clinical 
evidence of 
sepsis 
0.79 0.65 1.18 (0.51,2.53) 
Table 6.5: Odds ratios and p values for all forms of chorioamnionitis 
 (n=188) and clinical outcomes 
 
 
Clinical 
association 
Fisher’s exact 
(2-tail) 
Mid P exact 
(2-tail) 
Odds ratio and 
95% CI, mid P 
exact 
Apgar score <7 0.003 0.002 5.0 (1.9,11.9) 
interventional 
delivery 
<0.0000001 <0.0000001 6.8 (4.01, 11.8) 
admission to 
NICU 
0.05 0.03 3.4 (1.3,7.6) 
clinical 
evidence of 
sepsis 
0.02 0.01 3.4 (1.3, 7.7) 
Table 6.6: Odds ratios and p values for funisitis (n=64) and  
clinical outcomes 
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Clinical 
association 
Fisher’s exact 
(2-tail) 
Mid P exact 
(2-tail) 
Odds ratio and 
95% CI, mid P 
exact 
Apgar score <7 0.68 0.40 2.6 (0.12, 15.7) 
interventional 
delivery 
0.01 0.006 4.3 (1.5, 12.1) 
admission to 
NICU 
0.76 0.38 0 (0.00, 5.7) 
clinical 
evidence of 
sepsis 
>0.999 0.55 0 (0.00, 3.3) 
Table 6.7: Odds ratios and p values for inflammation of chorionic plate,  
free membranes and subchorionic fibrin (n=16) and clinical outcomes 
 
 
Clinical 
association 
Fisher’s exact 
(2-tail) 
Mid P exact 
(2-tail) 
Odds ratio and 
95% CI, mid P 
exact 
Apgar score <7 >0.999 0.665 1.5 (0.07, 8.4) 
interventional 
delivery 
0.29 0.21 1.7 (0.71, 3.9) 
admission to 
NICU 
0.38 0.19 0 (0.00, 1.8) 
clinical 
evidence of 
sepsis 
0.72 0.36 0 (0.00, 14.3) 
Table 6.8: Odds ratios and p values for chorionic plate inflammation  
(n=28) and clinical outcomes 
 
 
Clinical 
association 
Fisher’s exact 
(2-tail) 
Mid P exact 
(2-tail) 
Odds ratio and 
95% CI, mid P 
exact 
Apgar score <7 0.53 0.30 3.6 (0.16, 22.4) 
interventional 
delivery 
0.80 0.57 1.4 (0.31, 5.16) 
admission to 
NICU 
>0.999 0.44 2.4 (0.11, 14.7) 
clinical 
evidence of 
sepsis 
0.73 0.44 2.4 (0.11, 14.7) 
Table 6.9 Odds ratios and p values for free membrane inflammation  
(n=12) and clinical outcomes 
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Clinical 
association 
Fisher’s exact 
(2-tail) 
Mid P exact 
(2-tail) 
Odds ratio and 
95% CI, mid P 
exact 
Apgar score <7 >0.999 0.687 0.59 (0.02, 
3.25) 
interventional 
delivery 
0.001 0.009 2.52 (1.48, 
4.23) 
clinical 
evidence of 
sepsis 
0.175 0.087 0 (0.00, 1.25) 
admission to 
NICU 
0.478 0.326 0.48 (0.07, 
1.72) 
Table 6.10.Odds ratios and p values for subchorionic fibrin inflammation 
(n=68) and clinical outcomes 
 
6.5 DISCUSSION 
 
There are few pre-existing studies of unselected term cohorts to offer comparison to the 
data presented above. As noted in Chapter 2, rates reported at term range from 10% to 
35%, (38, 157, 158). The studies cited use variable definitions of chorioamnionitis and 
either do not report neonatal outcomes (38, 158) or report on a high-risk population 
(suspected meconium aspiration, premature delivery, post-mature delivery, 
oligohydramnios, previous stillbirth/premature delivery, maternal diabetes, maternal 
hypertension, substance abuse, fetal growth restriction, congenital infection and congenital 
anomalies) where neonatal death rates ran at 6.4% (157). One further study, published as a 
conference abstract only (220), examines the relationship of acute inflammation to birth 
weight, placental weight and gestational age in a population whose gestational age ranged 
from 28 – 44 weeks. The rate of funisitis in that population was reported as 18.5%. When 
considering the incidence of funisitis at term, 4% of one term population (n = 832) were 
found to have funisitis at delivery (221), while another study reports a rate of 5.1% (n = 
528) (217). 
 
In this study, histological features of ascending genital tract infection (ie an acute 
inflammatory cell infiltrate in one or more of free membranes, chorionic plate, 
subchorionic fibrin and umbilical cord) were found in 17% of cases, and the incidence of 
funisitis was 5.5%. Statistical analysis of the data generated by this study has found 
significant associations between one or more of the clinical outcomes studied for extensive 
placental inflammation (free membranes, chorionic plate, subchorionic fibrin) and funisitis.  
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For extensive placental inflammation, the association was with interventional delivery, a 
clinical decision reflecting concern, on the part of the clinical team caring for the labouring 
woman, for fetal and/or maternal wellbeing sufficient to expedite delivery – either assisted 
vaginal or operative. No further information is available from this study to analyse further 
the exact indications for interventional delivery in individual cases. 
 
Funisitis was significantly associated with all four adverse outcomes studied. Three of 
these (Apgar score < 7, suspected clinical sepsis, admission to the neonatal unit) are 
entirely concerned with fetal wellbeing, with suspected fetal sepsis evidently also a 
specific indicator for possible infection. The fourth – interventional delivery – as noted 
above is a marker of intervention by the clinical team indicated by either fetal or maternal 
wellbeing, or both. 
 
Patterns of acute inflammation in the placenta are often considered in terms of correlation 
with a fetal inflammatory response and a maternal inflammatory response, as discussed in 
Chapter 1, section 5.2. Notable in this study is the finding that the adverse outcomes 
identified fall into the category of a histological fetal inflammatory response. 
 
The fetal inflammatory response syndrome is characterized by activation of the fetal innate 
immune system, secondary to intra-uterine infection/inflammation (116). This was 
originally reported to be associated with raised interleukin 6 levels in cord blood (115) but, 
as further studies have been undertaken, elevated levels of other cytokines are being 
reported (116, 222). The fetal inflammatory response syndrome is overwhelming 
considered in the literature in the context of preterm delivery (115, 116, 216), and is in that 
context associated with a raised incidence of chronic lung disease, albeit with reduced 
respiratory distress syndrome (215). There appears to be strong evidence associating 
preterm chorioamnionitis with cerebral palsy (120).  
 
Assessing gestational-age independent effects of chorioamnionitis is more challenging, and 
may be difficult to achieve given continuing advances in neonatal care (223). Considering 
the specific question of the importance of funisitis at term – given the findings in the 
present study, relating funisitis to adverse clinical outcome – the literature is limited. 
Histological inflammation of the cord has been reported in term pregnancies in a small 
number of studies (217, 224), but is of uncertain significance: one of the cited 
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studies(217)describes significantly higher levels of cord blood interleukin 6 in preterm 
funisitis compared to term funisitis, and no cases of significant perinatal morbidity 
(congenital neonatal sepsis, suspected sepsis, respiratory distress syndrome, congenital 
pneumonia, bronchopulmonary dysplasia, intraventricularhaemorrhage or necrotizing 
enterocolitis).  
 
The findings of this study do, however, support the view that a fetally derived acute 
inflammatory response is associated with what may reasonably be described as lower grade 
but significant perinatal morbidity. The underlying mechanisms are not addressed by this 
study: the controversies relating to the presence or absence of fetal infection (158) and fetal 
inflammatory response (217) are noted. Further investigation of the significance of funisitis 
at term appears warranted.  
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6.6 CONCLUSIONS 
 
 
 
 188/1119 cases showed acute inflammation     
 Acute inflammation subgroups identified 
o no chorioamnionitis 
o funisitis 
o subchorionic fibrin inflammation  
o inflammation of chorionic plate,  
free membranes and subchorionic fibrin  
o chorionic plate inflammation  
o free membranes  
 Clinical outcomes studied as discrete variables  
o Apgar score < 7     
o Interventional delivery    
o NICU admission     
o Clinical sepsis  
 Statistically significant associations demonstrated between histological evidence of 
fetal inflammatory response and adverse neonatal outcome 
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______________________________________________________ 
CHAPTER 7: CLINICAL CORRELATION OF CHRONIC 
PLACENTAL VILLOUS HISTOLOGIC INFLAMMATION 
PATTERNS IN AN UNSELECTED POPULATION, WITH 
IMMUNHISTOCHEMICAL ANALYSIS 
______________________________________________________ 
 
 
Summary: 
 
 Cases of villitis of unknown etiology (VUE) identified 
o Subclassified according to involvement of chorionic villi and 
extent of inflammation 
 Five specific neonatal outcomes identified 
o Birthweight 
o Apgar score < 7 at one minute of age 
o Interventional delivery 
o Admission to neonatal intensive care 
o Intra-uterine growth restriction 
 Associations between villitis of unknown etiology and clinical 
outcomes  
 Pilot immunohistochemical studies 
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7.1 INTRODUCTION 
 
 
Chronic villitis is reported to affect between 5 and 15% of all third trimester placentas 
(132, 160, 225). Recognition of the lesion at less than 32 weeks gestation is virtually 
unknown and cases of chronic villitis at less than 32 weeks should be considered to be 
infectious until proven otherwise (46). Given that infection is extremely rare as a cause of 
chronic villitis in the third trimester (46, 226), the vast majority of cases of histologically 
recognised chronic villitis are described as villitis of unknown etiology (VUE).  
 
Some do advocate very rigorous exclusion of infection in every case of VUE (132), but the 
diagnosis can be secured on light microscopy with a characteristic non-uniform 
involvement of the placental parenchyma (in contrast to the more continuous involvement 
in infectious villitis) (46). On light microscopy, the distribution may be focal, diffuse or 
basal, with mixed patterns commonly seen (46). The characteristics of areas of 
involvement are those of one or more terminal chorionic villi infiltrated by a mononuclear 
infiltrate, together with stromal expansion (160), giving the villi a somewhat “clumped” 
architecture on low power microscopy, as shown below.  
 
 
Figure 7.1.Photomicrograph of placenta, 38 weeks gestation, showing clumped chorionic 
villous architecture (with a mixed infiltrate of small lymphocytes and macrophages) (x 4 
objective). 
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The clinical significance of VUE lies in multiple reports of an association between VUE 
and both intrauterine growth restriction (50, 159, 160, 227) and recurrent reproductive loss 
(46). There has been an additional suggested association with maternal obesity (160), and 
there are also reports of an increased incidence in ovum donation in vitro fertilization 
pregnancies compared with those achieved with maternal ova (228, 229) . Twin 
pregnancies have been shown to have considerable concordance for VUE, greater in 
monochorionicity than dichorionicity (230). 
 
Recognition of VUE as a specific histological lesion on light microscopy has been 
followed by multiple immunohistochemical investigations to elucidate the underlying 
mechanisms of disease. The lymphocytic infiltrate has been demonstrated, relying on 
differential sex chromosome expression in male fetuses, to be of maternal origin (231, 
232). HLA-DR expression, by macrophages within areas of villitis, has been reported on 
frozen section immunofluorescence (233). The lymphocytic population has been shown to 
be composed of predominantly CD8+ T cells (47, 234, 235). Syncytiotrophoblast has been 
shown to express intercellular adhesion molecule -1 (ICAM-1) (236). The T cell 
population has been demonstrated to have a T regulatory (Treg) phenotype. In the same 
study, HLA-DR expression by macrophages in VUE was confirmed but no HLA-DR 
expression by trophoblast demonstrated (237). 
 
In this study, the outcomes recorded are those from a single episode of ongoing 
intrauterine pregnancy and so no data are available to address the question of recurrent 
pregnancy loss. The main focus of this part of the study is thus to address the reported 
association between VUE and intrauterine growth restriction, and to report on a pilot study 
of a panel of immunohistochemical markers addressing mechanisms of disease in VUE. 
 
7.2 METHODS 
 
Recruitment to the study, recording of clinical data, microscopic and microscopic placental 
examination and immunohistochemical methods used are recorded in Chapter 2. The 
placental sampling protocol used in this study has previously been reported to support 
maximum detection of chronic villitis lesions (50). 
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7.3 STATISTICAL ANALYSIS 
 
Fisher’s exact and mid P values were calculated, together with odds ratios and 95% 
confidence intervals: please see Chapter 2. 
7.4 RESULTS 
 
Sixty three cases of VUE were identified in the cohort of 1119, 5.6% of cases. This rate is 
at the lower end of, but within the range of, the spectrum of rates reported in other cohorts . 
Twenty cases were categorised as high-grade, 23 as low-grade and 20 as low-grade 
multifocal. All cases of VUE identified fell within the gestational age range 37-41
+ 
weeks 
and so the control group of all non-VUE cases was restricted to the same gestational age 
range. There was no statistical significant difference between the number of cases with 
villitis of unknown etiology and controls for each completed gestational week. 
 
 VUE (%) 
n=63 
Non VUE (%) 
n=1019 
 
p value 
37 weeks 2 (3) 57 (6) 0.41 
38 weeks 5 (8) 135 (13) 0.30 
39 weeks 16 (25) 269 (26) 0.99 
40 weeks 17 (27) 290 (28) 0.92 
41 + weeks 23 (36) 268 (26) 0.10 
Table 7.1.Villitis of unknown etiology vs controls by gestational week 
 
Analysis of growth and neonatal outcomes 
 
As noted above, the case series previously reporting clinical outcomes in VUE report a 
consensus in favour of VUE being a lesion that is associated with intra-uterine growth 
restriction. This effect was not apparent in this cohort, in which both one way ANOVA 
testing (see table 7.1) and comparison of rates of IUGR (see Figures 7.2 and 7.3, and 
Tables 7.2 – 7.5) showed no evidence of a statistically significant difference in birthweight 
or IUGR. When considered in subgroups (high-grade VUE, low-grade focal VUE and low-
grade multifocal VUE) there was also no demonstrable difference between the 
birthweights recorded in each group. Z score-based analysis of birth weights, correcting for 
gestational week, did not demonstrate any significant difference between VUE and control 
cases (see Figure 7.4). 
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Subtype No of cases Mean birth 
weight 
SD 
no VUE 1019 3516 478 
high-grade VUE 20 3537 311 
low-grade focal VUE 23 3391 463 
low-grade multifocal VUE 20 3318 561 
 
Test for equality of variance:  
Chi
2 
= 6.39, degrees of freedom (df) = 3, p value = 0.09 
Table 7.2. Birth weight in VUE – one way ANOVA 
 
 
Further analysis of clinical outcomes which might be expected to be affected by an intra-
uterine environment presenting a degree of chronic fetal challenge – Apgar score at one 
minute, interventional delivery and admission to a neonatal intensive care unit (NICU  - 
was undertaken. This also showed no evidence of adverse outcome in the setting of VUE 
for both all forms of VUE considered together and on analysis of subtypes. This 
information is also presented in Figures 7.2 and 7.3, and Tables 7.2 and 7.3.  
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Figure 7.2. Clinical outcomes in villitis of unknown etiology
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 Apgar score <7 
 
 
(% cases) 
Interventional 
delivery 
 
(% cases) 
NICU 
admission 
 
(% cases) 
Intra-uterine 
growth 
restriction 
(% cases) 
No VUE 
(n=1019) 
33 
(3.2) 
237 
(23.2) 
54 
(5.3) 
11 
(1.1) 
all VUE  
(n=63) 
1 
(1.6) 
12 
(19) 
3 
(4.7) 
0 
(0) 
Table 7.3. Clinical outcomes in villitis of unknown etiology (all cases) 
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Figure 7.3. Clinical outcomes in VUE subtypes
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 Apgar score <7 
 
 
(% cases) 
Interventional 
delivery 
 
(% cases) 
NICU 
admission 
 
(% cases) 
Intra-uterine 
growth 
restriction 
(% cases) 
No VUE 
(n=1019) 
33 
(3.2) 
237 
(23.2) 
54 
(5.3) 
11 
(1.1) 
High-grade 
VUE (n=20) 
0 
(0) 
3 
(15) 
1 
(5) 
0 
(0) 
Low-grade 
focal VUE 
(n=23) 
0 
(0) 
1 
(4.3) 
1 
(4.3) 
0 
(0) 
Low-grade 
multifocal VUE 
(n=20) 
1 
(5) 
8 
(40) 
1 
(5) 
0 
(0) 
Table 7.4. Clinical outcomes in villitis of unknown etiology (subgroups) 
 
 
 
 
Clinical 
association 
Fisher’s exact 
(2-tail) 
Mid P exact 
(2-tail) 
Odds ratio and 
95% CI, mid P 
exact 
Apgar score < 7 0.78 0.51 2.1 (0.39, 44.0) 
Interventional 
delivery 
0.18 0.14 1.59 (0.86, 
3.12) 
NICU 
admission 
>0.99 0.91 1.12 (0.38, 
4.64) 
IUGR 
 
>0.99 0.51 0.0 (0.00, 5.11) 
Table 7.5.Odds ratios and p values for all VUE (n=63) and clinical  
outcomes. 
 
 
 
 
Clinical 
association 
Fisher’s exact 
(2-tail) 
Mid P exact 
(2-tail) 
Odds ratio and 
95% CI, mid P 
exact 
Apgar score < 7 >0.99 0.52 0.00 (0.00, 
5.04) 
interventional 
delivery 
0.57 0.41 0.58 (0.13, 
1.84) 
NICU 
admission 
>0.99 0.95 1.06 (0.19, 
22.7) 
IUGR 
 
>0.99 0.81 0.00 (0.00, 
5.04) 
Table 7.6. Odds ratios and p values for high-grade VUE (n=20) and  
clinical outcomes. 
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Clinical 
association 
Fisher’s exact 
(2-tail) 
Mid P exact 
(2-tail) 
Odds ratio and 
95% CI, mid P 
exact 
Apgar score < 7 >0.99 0.76 1.35 (0.06, 
7.68) 
interventional 
delivery 
0.03 0.02 0.15 (0.007, 
0.81) * 
NICU 
admission 
>0.99 0.94 0.81 (0.04, 
4.56) 
IUGR 
 
>0.99 0.78 0.00 (0.00, 
14.6) 
Table 7.7. Odds ratios and p values for low-grade multifocal VUE (n=20)  
and clinical outcomes. (*favours control group) 
 
 
 
 
Clinical 
association 
Fisher’s exact 
(2-tail) 
Mid P exact 
(2-tail) 
Odds ratio and 
95% CI, mid P 
exact 
Apgar score < 7 0.98 0.62 1.57 (0.08, 9.0) 
interventional 
delivery 
>0.99 0.98 0.98 (0.40, 
2.22) 
NICU 
admission 
>0.99 0.95 0.94 (0.04, 5.3) 
IUGR 
 
>0.99 0.81 0.00 (0.00, 
19.0) 
Table 7.8. Odds ratios and p values for low-grade focal VUE (n=23) 
and clinical outcomes. 
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Immunohistochemical studies 
 
Immunohistochemical studies were carried out on two sets of micro-arrays – VUE and 
controls, with 20 cases in each set. For ease of reference, table 5.4 is reproduced below as 
Table 7.6. 
 
Primary antibody Cell type/antigen 
CD3 T cell 
CD20 B cell 
HLADR Cell surface class II major 
histocompatibility complex 
CD68 Macrophage/monocyte series 
C4d Complement activation 
cleaved caspase 3 (Cl-Cas3) Apoptosis marker 
ICAM (CD54) Leukocyte/endothelial transmembrane 
adhesion molecule  
P selectin (CD62P) Activated endothelial/activated platelet 
transmembrane adhesion molecule  
Fox P3 T regulatory cell (TREG) phenotype 
Table 7.9. Immunohistochemical panel: target cell type/antigen  
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Figure 7.4. z scores (birthweights), VUE vs controls
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The outcomes of the immunohistochemical studies are shown in graphical and tabular form 
in Figure 7.5. The infiltrating inflammatory cell population showed increased expression of 
CD3, CD20, CD68, HLA-DR and Fox-P3 compared with controls. CD3, CD 20 and CD 
68 had a membranous pattern of staining.  HLA-DR also had a cell surface distribution, 
and appeared possibly to be localised to syncytiotrophoblast as well as the surface 
membranes of histiocytes, although the overlap between cell types in areas of dense 
inflammatory infiltrate was considerable. Fox-P3 had a nuclear staining pattern. CD3 and 
HLA-DR immunostaining is illustrated in Figure 7.6. 
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 Mean SD N Mean SD N 
CD3 246.00 176.00 20 3.76 2.93 20 
CD20 3.60 3.30 20 1.20 1.36 20 
CD54 3.56 3.30 20 14.80 34.20 20 
CD62p 0.38 0.86 20 1.86 2.49 20 
CD68 66.40 91.60 20 9.25 15.10 20 
C4d 2.85 4.36 20 3.76 13.80 20 
HLA-DR 10.80 7.37 20 2.22 3.18 20 
Cl-Cas3 40.40 34.10 20 24.30 34.60 20 
Fox- P3 32.20 48.20 20 0.00 0.00 20 
 
Figure 7.5. Immunohistochemical analysis:
VUE vs controls
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Figure 7.6.Immunohistochemical expression of CD3 (left) and HLA DR  (right) 
in a focus of villitis of unknown etiology (x 10 objective) 
 
7.5 DISCUSSION 
 
The results in this part of the study were perhaps the most surprising in the study overall, 
given the weight of findings in previous publications. The underlying reasons for this 
variation may not be entirely identifiable, but it is possible to speculate on some possible 
contributory factors to the differences between this study and those previously published.  
 
Apart from the small series of 50 cases dating from 2007-2008 (161), the three large case 
series which form the basis of the epidemiological evidence for the clinical outcomes seen 
in association with VUE date from 1976-1978 (159), 1979-1980 (50)  and 1995-1997 
(160). Clinical management regimes will evidently have evolved in the interval between 
those large case series (ranging from 529 to 7505 cases) and the present. Small for 
gestational age fetuses are likely to be recognised at an early point in pregnancy (238, 
239), with subsequent clinical management directed towards delivery of the fetus at the 
most advantageous point for subsequent neonatal wellbeing. With the advances in neonatal 
care since the conclusion of the last large case series examining VUE and growth 
restriction, the possibility exists that a subgroup of fetuses clinically affected by VUE is 
being delivered earlier than was the case ten or twenty years ago. As previously noted in 
the analysis of data from this study, there was a recruitment bias in the study design in that, 
in retrospect, favoured recruitment of low-risk women delivering at term. Those women 
presenting as an emergency, or those women delivering semi-electively pre-term, would 
have been less likely to be recruited in routine ante-natal clinics and less likely to have 
been approached about the ongoing research study in an emergency setting. It may thus 
have proven that this study selected out a number of pregnancies affected by VUE.  
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The findings in this cohort could, however, be consistent with two further interpretations: 
this cohort may represent a variant with outcomes (in this study) at the better end of the 
range or VUE may not, in fact, represent as serious a risk to fetal growth and well-being as 
has previously been thought. 
 
Immunohistochemical analyses were in keeping with previously reported studies (77, 240). 
As has recently been reported, a proportion of the inflammatory cell infiltrate has a Fox-P3 
positive T regulatory cell phenotype (237); a similar pattern was found in this cohort. 
There is thus no evidence that the phenotype of the inflammatory cell infiltrate in this 
study is substantially different from that reported in previous cohorts.  
 
In conclusion, this pattern of placental inflammation, which has previously been 
considered as incontrovertibly abnormal, requires additional study. An extended review of 
the data from previous studies (beyond the scope of the present study) is required, together 
with continuing investigation, possibly in the form of nested case control studies, into the 
significance of villitis of unknown etiology in the context of modern obstetric practice. 
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7.6 CONCLUSIONS 
 
 
 
 63/1119 cases showed villitis of unknown etiology (VUE) 
 VUE subgroups identified 
o High-grade VUE 
o Low-grade focal VUE 
o Low-grade multifocal VUE 
 Extended analysis of growth undertaken 
o One ANOVA of mean birth weights for gestation-matched controls 
o Identification of IUGR pregnancy rates in VUE and controls 
o z score analysis of VUE and controls corrected for gestational week 
 Clinical outcomes studied as discrete variables 
o Apgar score < 7 
o Interventional delivery 
o NICU admission 
o Intra-uterine growth restriction 
 No statistically significant associations between VUE and growth or adverse 
neonatal outcomes 
 Immunohistochemical studies   
o CD3, CD20, CD68 rich infiltrate 
o HLA-DR expression on histiocytes 
o HLA-DR expression on syncytiotrophoblast 
o T regulatory cell phenotype identified 
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____________________________________________________ 
CHAPTER 8: DISCUSSION 
______________________________________________________ 
 
 
Summary: 
 
 
 Study design 
 Placental macroscopic examination 
 Placental histological examination 
 Modern obstetric and neonatal care 
 Study population 
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8.1 REVIEW OF FINDINGS IN THIS STUDY 
 
This study has addressed the question of which placental lesions are significant for adverse  
perinatal outcomes in a low-risk population delivering at or near to term. Following initial 
analysis of the data, four specific lesions were identified for further evaluation: umbilical 
cords with coiling > 90th or < 10th centile; placental infarction; villitis of unknown 
etiology and acute inflammatory cell infiltrates consistent with ascending genital tract 
infection. 
 
There are considerable numbers of publications suggesting that placental  examination is, 
in many cases, the key to understanding adverse events in pregnancy and the neonatal 
period (28, 110, 111, 113, 241-244), and many studies – as reviewed extensively in the 
preceding chapters – suggest that specific macroscopic and microscopic lesions are 
positively associated with significant clinical issues. 
 
Analysis of the data obtained from this study shows no association between the clinical 
outcomes studied and umbilical cord coiling > 90th or < 10th centile, chronic villitis of 
unknown aetiology or placental infarction.  
 
Funisitis at term and extensive acute inflammation of the chorionic plate were identified as 
being associated with a number of neonatal events. Significant associations between other 
histological patterns of ascending genital tract infection and adverse neonatal outcomes 
were not found. It should, however, be noted that, even for funisitis and chorionic plate 
inflammation in this study, the clinical neonatal care provided appeared sufficient to result 
in discharge to home of a healthy infant. Long-term follow-up did not form part of this 
study protocol. 
 
Specific reasons for the variation between present findings and previously published 
studies have been addressed in individual Chapters but a number of common key themes 
emerge for review: effective study design, criteria for macroscopic examination of the 
placenta, criteria for histological examination of the placenta, modern obstetric and 
neonatal care, and the nature of the population in this study.  
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Design of this study & design of previous studies in this field 
 
Cohort studies are designed to study incidence, causes and prognosis (245). In this study, 
the incidence and short-term outcome of a number of specific placental lesions were 
studied.  This format was probably the most realistic methodology that could have been 
selected to investigate the research question asked and, although time-consuming and 
relatively expensive, has provided robust information about 1119 subjects delivering at or 
close to term. As has been noted, a large number of studies reporting positive data in this 
field are retrospective case-control studies. 
 
While the recruitment bias in the present study (tending to recruit low-risk women at or 
near term) has been recurrently acknowledged, the risks of bias inherent in smaller, 
retrospective case control studies are large and rarely explored, with both sampling bias 
and retrospective analysis bias introduced into case control studies from the outset (245) . 
There is also no means of establishing the existence of any existing research data 
supporting the findings in this study, given the acknowledged tendency within the research 
community to publish only positive results (246). 
 
When attempting to review the results of previously published work in this area, the effects 
of clinical heterogeneity should be considered. This is of critical importance in the 
construction of a systematic review and meta-analysis, but even without undertaking a 
formal exercise such as this, the presence of clinical heterogeneity when comparing other 
studies cannot be overlooked. Clinical heterogeneity is introduced when there are 
differences amongst patient selection, baseline morbidity, definitions of disease, clinical 
interventions and duration of follow-up (247, 248). The literature reviewed to support this 
study has indeed shown considerable heterogeneity and must be at least contributory to the 
variation in findings between this study and others. 
 
Criteria for macroscopic examination of the placenta 
 
There continues to be disagreement relating to the most effective method of examining a 
placenta macroscopically. It is said that placental infarcts  - particularly fresh infarcts – are 
more easily identified visually post-fixation, although palpable as a firm lesion when 
unfixed. Areas of downstream villous avascularity are also said to be difficult to detect in 
the unfixed state (3).  Placental weight is, however, increased by around 7% following 
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fixation (249). On balance - given the need for consideration of fetal:placental weight in 
this study - examination of the unfixed placenta was preferred.  
 
The potential for interobserver error in the macroscopic examination of the placentas in 
this study certainly existed, as two prosectors undertook placental examination during the 
course of recruitment. One prosector was a consultant histopathologist (FAJ) while the 
other was a research fellow in obstetrics (SP). SP was provided with extended training by 
FAJ in placental examination, at the outset of the study, including a number of supervised 
sessions. Any error in macroscopic placental examination is thus, in this study, likely to be 
systematic, given that the criteria for recognition of abnormality were essentially those of 
one prosector (FAJ). 
 
Criteria for histological examination of placenta 
 
There are a number of reporting schedules for various placental lesions. In this study, 
histological diagnoses of specific conditions were made with as much reference to 
previously published descriptions as was possible. In particular, all possible lesions, no 
matter how low-grade, were identified by re-screening of cases which would, under routine 
clinical practice in the laboratories involved in this project (Addenbrooke’s and Great 
Ormond Street), be reported as normal. Moderation of diagnostic standards used was 
undertaken at the outset of the project, by dual screening of approximately 10% (100/1119) 
of cases by two consultant histopathologists. (FAJ and NJS). 
 
Modern obstetric and neonatal care 
 
Real-time scanning and progressive improvements in image quality have led to the 
generation of validated fetal growth charts (250, 251), permitting earlier and more accurate 
detection of fetal growth impairment (252). Growth charts have continued to be reviewed 
and revised (253-256). While the effectiveness of current screening for growth restriction 
by tracking fundal height (257, 258) and routine Doppler/ultrasound (259, 260) continues 
to be debated, fetal biometry and Doppler flow are the mainstay of surveillance of fetal 
growth and wellbeing in detected cases of fetal growth impairment (257).  
 
Other issues relating to clinical care, such as birth during weekday normal working hours 
(261, 262) and place of birth (home, midwife-led birth unit, obstetric units) (151, 182), are 
associated with variations in perinatal mortality and morbidity. 
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Neonatal care has advanced rapidly in recent years (263), but while neonatal mortality has 
been carefully tracked and demonstrated to be falling (7.7/1000 in 1980 to 2.9/1000 in 
2010) (264), large population-based studies reporting incidences and trends in neonatal 
morbidity are rare. 
 
 
 
Studies describing neonatal morbidity tend to report on long-term outcomes following 
premature birth. The target population of the present study was a low-risk term cohort, 
with a low frequency of adverse neonatal outcomes. It is acknowledged that tracking 
neonatal outcomes data are a challenging area (265). A few studies exist reporting 
outcomes of low-risk term infants: one records an incidence of  primary outcome events 
including birth trauma, severe morbidity (meconium aspiration, encephalopathy) and 
mortality of <0.5% (151), while in another the incidence of neonatal intensive care unit 
admission was between 5.2% (term vaginal births) to 9.8% (term elective caesarian birth) – 
a rate much higher than historical UK admission rates of 0.3% (266). 
 
In summary, there is good evidence from the obstetric literature that clinical surveillance of 
ongoing pregnancy continues to improve, and the neonatal mortality statistics available 
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would tend to suggest that modern practices in both obstetric and neonatal care have 
improved perinatal outcomes. On the limited evidence available, the rate of relatively low-
grade neonatal morbidity appears low. It is also noted that, as might be expected, factors 
other than the intrinsic wellbeing of the feto-placental unit affect neonatal outcomes in 
low-risk populations, including such variables as place and time of birth. 
 
These observations are important and relevant in the context of the present study. 
Literature dating from a number of years ago may report outcomes in clinical cases which 
are now managed more pro-actively, altering pregnancy outcome in the setting of a 
placental lesion previously associated with adverse outcomes. While the contribution of 
improving clinical care to the largely good perinatal outcomes in this study -  versus the 
possibility that lesions previously suspected of inducing significant pathology are in fact 
completely innocuous - is difficult to assess, it must remain under active consideration 
when considering the implications of the findings in this study. 
 
Study population 
 
The composition of the population in this study was overwhelmingly low-risk and at term: 
this is, as discussed elsewhere, rare in studies evaluating of pregnancy outcomes. 
Management of low-risk pregnancy in the United Kingdom is minimally interventional, 
with most women being offered a late first trimester dating scan, serum screening and a 
midtrimester anomaly scan (239), the regime thus offered to the women in this cohort.  
 
High-risk women are identified either by antecedent clinical history or events in an 
ongoing pregnancy. The management of high-risk pregnancy has become more 
interventional in more recent years and this subgroup of pregnant women will thus be 
offered a more complex management plan as discussed above (267). Specific events 
conferring high-risk on a current ongoing pregnancy are highly variable (199, 203, 267-
269), and include the identification of fetal anomalies not otherwise addressed in this study 
(270-272). High-risk women did not form a viable study group in the current population, 
given that recruitment was focused on routine antenatal clinics and relatively 
uncomplicated term deliveries. 
 
Placing the outcomes of this study into the context of those for other studies reporting low-
risk population outcomes does, however, show (as far as can be determined) comparable 
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rates of obstetric and neonatal events between this study population and other term 
populations (see data summarized in Chapter 3). Neonatal primary outcome measures in 
large population studies are very often set at the severe end of the spectrum (perinatal 
death, birth injury, low birth weight) (150, 151). Placing this study’s findings in context 
has thus relied more on individual studies reporting a smaller number of outcomes. Where 
possible – eg birth weights – nationally reported statistics were employed (see Chapter 3). 
 
A very large number of studies report specifically on placental lesions in the context of the 
clinical outcome of preterm deliveries (31, 44, 103, 106, 214, 273-280), and providing a 
comprehensive review of them is beyond the scope of the present study. Reference to 
studies of preterm placentas is, however, relevant to this study of term infants in that 
placental findings in the preterm population - such as florid acute inflammatory lesions and 
maternal vascular lesions seen in the setting of pre-eclampsia - are associated with adverse 
preterm outcomes. Some of the lesions reviewed in this study, specifically acute 
inflammatory lesions and placental infarction, are morphologically reminiscent of those 
correlated with severe adverse events in the preterm infant, but appear in this study to show 
more benign clinical associations. Any inclination to extrapolate directly from preterm to 
term placentas does not, on the present evidence, appear justified. 
 
 
Conclusion 
 
This study reports on the clinical and placental findings in a cohort of 1119 women, 
predominantly low-risk and delivering at term. Analysis of specific placental lesions, 
previously identified by other researchers as conferring significant clinical risk for adverse 
perinatal outcome, was undertaken.  The infants within this cohort were largely able to 
withstand any adverse effects of the placental lesions examined.   
 
The possible underlying reasons for this are considered above, and may be multifactorial. 
The design of previously reported studies may have introduced a considerable degree of 
bias into their conclusions. While it is important not to overlook any possible flaws in the 
design of the current study, there is no reason to believe that the methodology of either 
macroscopic or microscopic examination has introduced systematic bias into this study. It 
is acknowledged that the design of the current study did introduce recruitment bias in 
favour of low-risk term pregnancies – but the rate of specific placental lesions in this 
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population was comparable with other studies, and so the relative absence of adverse 
outcomes in this study continues to require explanation. 
 
The term infant, with more mature systemic physiology and a larger placenta with 
increased reserve, may prove be much less vulnerable to the impact of a lower grade 
placental abnormality. The mothers in this study were predominantly healthy, low-risk 
women. The context, in this study, of increasingly advanced obstetric and neonatal care 
may have contributed to the observed outcomes, by overcoming the potentially adverse 
effects of the placental lesions present. 
 
In the last analysis, however, it may prove simply to be the case that the placental lesions 
examined in this study are largely innocuous. This study is thus of importance in 
contributing to a better understanding of the pathophysiology of adverse term neonatal 
outcome, and challenges a tendency in both medicolegal and clinical practice to attribute a 
range of adverse outcomes to underlying placental pathology (281). The future directions 
of further investigations which may be undertaken in this field are considered in the 
following chapter. 
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_________________________________________________ 
CHAPTER 9: FURTHER WORK 
______________________________________________________ 
 
 
Summary points: 
 
 Further population-based studies 
 Expansion of systematic review format 
 Laboratory-based tissue analysis 
o Immunohistochemistry 
o Proteomic analysis 
o microRNA studies 
o Evaluation of biomarkers 
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9.1 INTRODUCTION 
 
Inevitably, at the conclusion of any research study, some initial questions remain 
unanswered, while the results of the study itself raise further issues for exploration. This 
study had many components and the future directions of new studies which could develop 
from this work are set out below. 
9.2 FURTHER POPULATION-BASED STUDIES 
As has been discussed extensively in the preceding chapters, a fundamental objective of 
this study was to determine the incidences of a number of specific placental lesions and 
link these lesions with clinical outcomes. It has thus been demonstrated that funisitis at 
term is a potentially significant lesion for neonatal well-being, even in unselected low-risk 
pregnancies. Conversely, and in contrast to a number of previously published studies, this 
study did not identify a strong link between high-grade villitis of unknown etiology and 
neonatal outcomes, including birth weight.  
A separate, but also highly important, learning point from this project is that daily 
collection and examination of large numbers of placentas from low-risk deliveries 
represented a huge logistical task, in many ways greater than had been anticipated at the 
inception of the study.  Given, however, that the work is complete, and the incidence rates 
for a range of histological lesions for the Cambridge population delivering at the Rosie 
Hospital is now defined, further large cohort based studies in Cambridge are unlikely to be 
significantly useful: rather, opportunities for more targeted placental examination now 
exist. 
In an era of rapid discharge of low-risk mothers and infants from delivery units, 
readmission with suspected neonatal sepsis, or indeed less specific events such as 
readmission with poor feeding/neonatal dehydration/poor weight gain, are events which 
both undermine early mother and baby attachment and represent cost pressure in a health 
care system which remains under considerable financial strain. Care pathways should 
include rapid and simple investigations which can provide early identification of potential 
problems. It would, for example, be extremely interesting, and potentially very useful, to 
investigate rates of funisitis in early readmissions following discharge home. More 
generally, then, design of further study protocols with defined clinical outcomes examined 
in a nested case control format, would be both cost efficient and of potential benefit to new 
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mothers and infants by assisting those who care for them to make more appropriate and 
timely decisions relating to their wellbeing. 
9.3 EXPANSION OF SYSTEMATIC REVIEW FORMAT 
 
There was no certainty, at the discussion stage of drawing up this study, that application of 
the systematic review format to macroscopic and microscopic placental findings – linked 
to clinical outcomes – would be fruitful. While very familiar to practicing clinicians, to 
whom the Cochrane review database is a day-to-day resource which assists in planning 
treatment plans for individual patients, systematic review analysis is not well established in 
histopathology. This format has, however, been extremely useful, not least in supporting 
extended literature searches for all topics included in this study. The core concept applied – 
ie, that the more familiar treatment intervention can be replaced by considering the 
suspected pathological event as the “intervention” for analysis – has been shown to be 
workable. Also noted more specifically in the systematic review of cord coiling was the 
degree of heterogeneity amongst previously published studies, thus highlighting the 
requirement for high-quality cohort studies with reduced risks of bias. 
Having piloted the format for analysis of cord coiling outcomes, the next step is to examine 
other pathological lesions in the same manner, assuming sufficient studies exist to support 
the format.  
Detailing the outcomes recorded for the Cambridge cohort in the setting of a relevant 
systematic review is the most likely next stage of investigation to follow on from this 
project. To this end, it is pleasing to report that Professor Peter Russell (Melbourne), one of 
the earliest investigators in the field of villitis of unknown etiology, has kindly sent his 
original research books and papers to the present candidate in May 2012, to support a 
systematic review in this particular field. 
9.4 LABORATORY-BASED TISSUE ANALYSIS 
 
Immunohistochemistry 
Extension of the pilot immunohistochemical studies undertaken is indicated, with 
particular focus on immune system activation and apoptotic pathways. As discussed below, 
these pathways, once established by immunohistochemistry to be activated in specific 
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placental abnormalities, may subsequently be further investigated by protein and nucleic 
acid analysis. 
 
Proteomics 
A proteome (282, 283) is a set of proteins expressed by a given genome in a specific time 
and space. This definition reflects the unique properties of a proteome, the composition of 
which is regulated by both intrinsic and extrinsic factors as summarized in Figure 9.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.1.Diagram of cell summarizing contribution of extrinsic and intrinsic factors 
modulating proteome expression. 
 
A good biomarker for a specific disease should have several characteristics, as given in 
Table 9.1. No equivalent of PCR amplification exists in the proteomic field, and,  for a 
number of clinical conditions, the concept of a single specific biomarker for disease has 
nucleus 
Extrinsic factors: 
 age 
 gender 
 comorbidity 
 hormones 
 cytokines 
 temperature 
 drugs 
protein 
Intrinsic factors: 
 conformation 
 post-translational 
modification 
 alternative splicing 
 secretion 
 stability 
 
      
 Page |  133 
been superseded by the recognition that a panel approach to analysis of biomarkers is much 
more specific and sensitive (284).  
 
Specific to organ/disease process 
Segregates to clinical entities 
Not present (or not increased) in diseases sporadically associated with milder forms of the 
disease 
Not present in healthy individuals 
Present in sufficient quantity in blood for reliable measurement 
Stable in blood (serum or plasma) with storage 
Table 9.1.Minimum criteria of a biomarker 
Proteomic studies most commonly report findings validated in biological fluids (most 
commonly serum and plasma) with the biomarker(s) selected indicating damage to the 
organ of interest, eg myocardium in ischaemic heart disease (285) or cell type in malignant 
disease (284). The alternative approach is that of primary identification of biomarkers 
within tissue with secondary validation in serum or other biological fluid analysis. 
A small number of studies of proteomic analysis exist in the analysis of placental disease.  
Sampling of amniotic fluid for proteomic analysis of inflammatory markers has, for 
example, been reported in the context of histological chorioamnionitis and villous tissue 
has been analysed in a small series of early pregnancy loss (286, 287).  
Future nested case control studies as described above provide the opportunity for extended 
immunohistochemical panels being translated to more complex proteomic analysis. In this 
context, newly described methodologies for analysis of the proteome in tissue sections has 
recently been reported (288).  
MicroRNA studies 
Small, non-coding RNAs are described as microRNAs (miRNAs): as non-coding RNAs, 
no protein product is transcribed. Regulation of miRNAs is effected by post-transcriptional 
processing of precursor transcripts to regulatory RNAs – a reduction from around 60 
nucleotides to around 20 is common (289).  Key miRNA processing genes, by regulating 
the conversion of precursor transcripts to active miRNAs, control the levels of active 
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mRNAs within the nucleoplasm – the Dicer gene, for example, is an important miRNA 
processing gene (290). Processing results in variations of levels of miRNA compared with 
their precursor transcripts, and it is variations in miRNA levels which appear to be linked 
with specific disease processes. The role of miRNAs in gene transcription is summarized 
in Figure 9.2 – as indicated, the target of miRNAs is messenger RNA (mRNA), which is 
either inhibited or destroyed in the downstream pathways. 
 
 
 
Figure 9.2.The role of miRNAs in gene transcription . 
 
Detection of miRNAs has become technically much more feasible in the last decade, with 
microarray analysis, deep sequencing, realtime PCR, Northern blotting and in situ 
hybridization all established techniques. The key aspects of each approach are given in 
Table 9.2. 
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microRNA 
detection 
method 
methods key points  
microarray  RNA extracted from cells or 
tissues 
 direct labeling of miRNA 
(fluorescent nucleotides) 
 
 does not support 
quantitative detection 
  probes must allow for 
short length of miRNAs 
 
deep sequencing  RNA isolated and 
fragmented 
 cDNA synthesis 
 ligation of adaptor 
(fluorescent 
oligonucleotide) to 
fragments 
 amplification of millions of 
sequence (automated) 
 ≈ 20 nucleotide sequences 
selected and mapped to 
genome of interest 
 good for low copy number 
– may be just a few 
molecules of miRNA/cell 
 no requirement for primer 
so “unbiased” technique – 
all RNA is captured  
 quantitative detection 
realtime PCR  RNA isolated and 
fragmented 
 cDNA synthesis 
(specialized primers 
required) 
 quantification against 
synthetic miRNA copies 
 technically challenging – 
binding affinity of primers 
difficult to balance 
Northern blot  RNA extracted 
 RNA fractionated 
(electrophoresis) 
 probe detection 
 large amounts of RNA 
required 
in situ 
hybridisation 
 whole mount preparations   
 probes applied directly to 
tissues 
 precursor miRNA easier to 
detect (longer) 
 modified probes required 
for shorter sequences 
Table 9.2.Summary of detection methods for miRNAs 
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MicroRNAs are of clinical interest in that the gene expression they regulate is increasingly 
recognized to be important in a range of diseases  - cardiovascular (289), malignant (291, 
292) and, more recent, immune disorders (293).  Detection of miRNAs in plasma includes 
the detection of placental miRNAs in pregnancy (294). While this is evidently of interest in 
the context of antenatal diagnosis of fetal genetic disorders, the potential for investigation 
of intrinsic placental parenchymal disorders is real. 
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APPENDICES 
 
______________________________________________________ 
 
 
 APPENDIX A: LREC APPROVAL 
 
Cambridgeshire 3 Research Ethics Committee 
(formerly Peterborough & Fenland Research Ethics Committee) 
Victoria House 
Capital Park 
FULBOURN 
Cambridge 
CB21 5XB 
 
Telephone: 01223 597597  
Facsimile: 01223 597645 
05 June 2007 
 
Dr Flora Jessop 
Consultant Paediatric/Perinatal Pathologist 
Department of Pathology, Box 235 
Addenbrooke's Hospital 
Hills Road 
Cambridge 
CB2 0QQ 
 
 
Dear Dr Jessop 
 
Full title of study: Outcomes in pregnancy and the neonatal period: 
correlation with placental examinations  
REC reference number: 07/Q0106/51 
 
Thank you for your letter of 08 May 2007, responding to the Committee’s request for 
further information on the above research and submitting revised documentation. 
 
The further information was considered at the meeting of the Sub-Committee of the REC 
held on 04 June 2007.  A list of the members who were present at the meeting is attached. 
 
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the 
above research on the basis described in the application form, protocol and supporting 
documentation as revised. The favourable ethical opinion is conditional upon the revised 
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Consent Form being given an updated version number and/or date. Please send the 
Committee a copy of the revised Consent Form as soon as possible. Please note that the 
approved Patient Information Sheet is the revised sheet of 080507. 
 
Ethical review of research sites 
 
The Committee has designated this study as exempt from site-specific assessment (SSA.  
There is no requirement for [other] Local Research Ethics Committees to be informed or 
for site-specific assessment to be carried out at each site. 
 
Conditions of approval 
 
The favourable opinion is given provided that you comply with the conditions set out in 
the attached document.  You are advised to study the conditions carefully. 
 
Approved documents 
 
The final list of documents reviewed and approved by the Committee is as follows: 
  
Document    Version    Date    
Application (Lock code: AB/106222/1)  19 March 2007  
Investigator CV: Dr Flora Jessop   15 March 2007  
Protocol  1.1  19 March 2007  
Covering Letter: Re initial application    19 March 2007  
Letter from Sponsor: Priya Shimoga, Addenbrooke's R&D   22 March 2007  
Patient Information Sheet    08 May 2007  
Participant Consent Form      
Participant Consent Form      
Response to Request for Further Information: Letter from Dr Flora 
Jessop  
 08 May 2007  
Letter from funder: Keith Day   30 October 
2006  
Applicant's checklist    19 March 2007  
 
R&D approval 
 
All researchers and research collaborators who will be participating in the research at NHS 
sites should apply for R&D approval from the relevant care organisation, if they have not 
yet done so.  R&D approval is required, whether or not the study is exempt from SSA.  
You should advise researchers and local collaborators accordingly. 
 
Guidance on applying for R&D approval is available from 
http://www.rdforum.nhs.uk/rdform.htm. 
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees (July 2001) and complies fully with the Standard Operating 
Procedures for Research Ethics Committees in the UK. 
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Feedback on the application process 
 
Now that you have completed the application process you are invited to give your view of 
the service you received from the National Research Ethics Service.  If you wish to make 
your views known please use the feedback form available on the NRES website at: 
 
https://www.nresform.org.uk/AppForm/Modules/Feedback/EthicalReview.aspx 
 
We value your views and comments and will use them to inform the operational 
process and further improve our service. 
 
07/Q0106/51 Please quote this number on all correspondence 
 
With the Committee’s best wishes for the success of this project 
 
Yours sincerely 
 
 
 
Mr Stuart Kent 
Vice-Chair 
 
Email: lynda.mccormack@eoe.nhs.uk 
 
 
Enclosures: List of names and professions of members who were present at the 
meeting and those who submitted written comments 
 
Standard approval conditions  
 
 
 
Copy to: Dr Claudia Rizzini 
Research and Development Manager 
R & D Department, Box 277 
Addenbrooke's Hospital 
Hills Road 
Cambridge 
CB2 0QQ  
 
Cambridgeshire 3 Research Ethics Committee 
 
 
Attendance at Sub-Committee of the REC meeting on 04 June 2007 
 
  
Written comments received from:  
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Name   Position (or reason for attending)   
Dr Doug Johnston  Lay member (retired consultant paediatrician)  
Mr  Stuart   Kent  Retired consultant surgeon  
 
 
In attendance:  
 
Name   Position (or reason for attending)   
Mrs Lynda McCormack  REC Assistant Administrator  
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APPENDIX  B - PATIENT INFORMATION LEAFLET AND CONSENT FORM 
Studies on your Placenta 
 
You are being invited to take part in a research study.  Before you decide it is important 
for you to understand why the research is being done and what it will involve.  Please take 
time to read the following information carefully. Talk to others if you wish. This leaflet: 
Outlines the aim of the study and what will happen to you if you take part.   
Outlines more detailed information about the conduct of the study.  
Please do ask us if there is anything that is not clear or if you would like more information. 
Take time to decide whether or not you wish to take part.   
 
2.  What is the purpose of the study?  
This study focuses on the placental examination and is being carried out jointly between 
the Rosie Hospital, Addenbrooke’s Histopathology Department & Great Ormond Street 
Hospital for Sick Children. We plan to examine placentas from women delivering their 
babies at the Rosie over a two year period, and will correlate the findings to pregnancy 
outcome and establish baseline features of the placenta. 
 
3.  Why have I been chosen?  
We are asking all mothers who are expecting one baby (i.e. not twins) booking at the 
Rosie.  
 
4.  Do I have to take part?  
No.  It is up to you to decide whether or not to take part.  If you do, you will be given this 
information sheet to keep and be asked to sign a consent form. Once you have signed the 
consent form, we will send your placenta for pathological examination and there is nothing 
further you would need to do.  
 
5.  What will happen to me if I take part?  
We are asking only one thing: to be able to examine your placenta (afterbirth) once baby is 
born. It is normally disposed of, however we will examine it in the laboratory and link the 
details of your pregnancy outcome anonymously with your maternity and baby’s records. 
This study will not in any way affect the care you receive, your appointments or delivery. 
You will not be contacted after the study is over. 
 
6.  What do I have to do?  
You will be provided the relevant information of the study and then asked if you wish to 
take part in the study. You then need do is to sign the consent form (part 2) attached to this 
information sheet. 
 
7.  What are the possible benefits of taking part?  
Normally, placentas are not sent for pathology examination. There is no direct benefit to 
you from taking part in the study, however as you are participating in this study, we’ll 
examine the afterbirth and a report would be available for, if requested by your doctor in 
the hospital looking after you during the pregnancy.  
 
8.  What happens to my placenta?  
Studies have linked the pregnancy and neonatal outcomes with the changes in the placenta. 
We’ll examine the placentas and link the examination findings to the pregnancy and 
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neonatal outcome. The placenta (afterbirth) will be examined in the laboratory and some 
small pieces of tissue will be taken and examined under the microscope. The tissue will 
then be held in long term (minimum 25 years) secure storage at Addenbrooke’s and Great 
Ormond Street Hospitals. These tissues from the placenta will be used for the further 
studies which will be subjected to ethical approval.   
 
9.  Will my taking part in the study be kept confidential?  
We will follow ethical and legal practice and all information about you will be handled in 
confidence. Information will be collected by one of the research team members. The 
anonymised database linking placental pathology with all outcome data will be kept on a 
restricted research database at Addenbrooke’s.  
 
10. What if there is a problem?  
If you have a concern about any aspect of this study, you should ask to speak to the 
researchers who will do their best to answer your questions (S Pathak, ext: 58137). If you 
remain unhappy and wish to complain formally, you can do this through the NHS 
Complaints Procedure. Details can be obtained from the hospital. 
 
11. What will happen to the result of the study?  
We intend to use the result of this study in future pregnancies management. We intend to 
publish the results and you will not be identified in any report/publication. 
 
12. Who has reviewed the study?  
All research in the NHS is looked at by independent group of people, called a Research 
Ethics Committee to protect your safety, rights, wellbeing and dignity. This study has been 
reviewed and given favourable opinion by Peterborough Research Ethics Committee.  
 
13. Who will be doing the research?  
The research group is: Mr C Lees (Consultant in Obstetrics and Fetal Medicine), Mr G 
Hackett (Consultant Obstetrician and Gynaecologist), Dr E Murdoch (Consultant 
Neonatologist), Dr F Jessop (Consultant Paediatric Pathologist), Dr N Sebire (Consultant 
Pathologist), Dr L Hook (Pathology Subspeciality Fellow) and Dr S Pathak (Research 
Fellow in Fetal Medicine). The study funded jointly by Addenbrooke’s Charities (Charity 
number: 1048868), Cambridge Fetal Care, and Great Ormond Street Hospital. 
  
14.  Contact Details: 
The research fellow conducting this study is: Dr Sangeeta Pathak If you have any queries 
about this study, observations or complaints, then please contact her by telephone 
(extension 58137, or through switchboard via bleep) or email: 
sangeeta.pathak@Addenbrooke’s.nhs.uk 
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Patient Identification Number for this trial: 
 
 
CONSENT FORM 
Title of Project: Placental Correlates of Pregnancy and Neonatal  
   Outcomes. 
 
 
Name of Researcher: Dr Sangeeta Pathak 
 
      
1. I confirm that I have read and understand the information sheet dated…………   
for the above study. I have had the opportunity to consider the information, ask 
questions and have had these answered satisfactorily  . 
 
 
2. I understand that my participation is voluntary and that I am free to withdraw at  
  any time, without giving any reason, without my medical care or legal rights   
 being affected . 
 
3. I understand that relevant sections of any of my medical notes, my baby’s medical  
Notes and data collected during the study, may be looked at by responsible    
individuals from the research team of Cambridge University Hospitals NHS  
Trust and Great Ormond Street Hospital where it is relevant to my taking part in  
this research. I give permission for these individuals to have access to my records   . 
 
4.  I consent for my placental tissues to be stored at the Addenbrooke’s Hospital and   
     Great Ormond Street Hospital for further studies   .      
   
5.   I agree to take part in the above study    .    
 
 
______________________ ________________ ____________________ 
Name of Patient Date Signature 
 
 
 
______________________           ________________                ____________________ 
Name of Person               Date                     Signature 
Taking consent 
 
 
  When completed, 1 for patient; 1 for researcher site file; 1(original) to be kept in medical notes. 
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APPENDIX C: HISTOPATHOLOGY REQUEST FORM  
 
 
East Anglia Perinatal and Paediatric Histopathology Services  
and Fetal Medicine Department. 
 
REQUEST FORM  
 
(Study contact: Dr Sangeeta Pathak ext 3660.) 
 
Request for Examination of Placenta for the Studies on Your Placenta Project  
LREC Reference no. 07/Q0106/51 (A completed consent form must be filed in the notes). 
 
Section 1 
 
 
 
 
 
 
Gestation: 
 
Delivery date: 
 
 
Ensure that, if clinically required, samples 
for Cytogenetics + Microbiology have 
been taken. 
 
 
If placental histopathology is required, 
complete green form as normal and 
enclose with this form. 
 
 
 
Section 2: 
 
Name of person completing this form: 
 
 
Name of person taking consent: 
 
 
Section 3 
FOR RESEARCH USE ONLY 
 
 
 
RNA later sample taken: 
 
 
 
 
 
 
(Page 2: for laboratory use only)
 
 
Addressograph 
Y N 
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Page 2: please note, this page for laboratory use only 
 
Department of Histopathology, Addenbrooke’s Hospital Cambridge 
 
PLACENTA WEIGHT SHEET 
 
Number 
 
 
Name 
 
Hospital number 
 
 
Date 
 
Technician 
 
 
Path 
 
 
MACRO 
 
 
 
 
 
 
 
Trimmed 
 
 
Dimensions 
 
 
Cord length 
 
 
Cord diameter 
 
 
Number of 
vessels 
 
 
Insertion 
 
 
Direction of coil 
 
 
Coiling 
 
 
 
 
 
1 
 
 A 
 
2 
 
 
B 
 
3 
 
 
C 
 
4 
 
 
D 
 
5 
 
 
E 
 
6 
 
 
F 
 
7  G  
 
8 
 
 
H 
 
9 
 
 
J 
 
10 
 
 
K 
 
11 
 
 
L 
 
12 
 
 
M 
 
13  
N 
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MICRO 
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APPENDIX D – PROTOCOL FOR MACROSCOPIC EXAMINATION OF 
PLACENTAS 
 
 
PROTOCOL FOR EXAMINATION OF PLACENTAS 
 
Macroscopic examination:  
Placentas will be received in the histopathology department, Addenbrooke's Hospital.  The 
specimens should be fresh and placed in labelled clean plastic buckets with a labelled 
request form.  Cord and membranes will be trimmed from the fresh specimens.  Samples 
from both fetal and maternal surfaces will be taken and snap frozen in liquid nitrogen. 
 
Checklist for cord examination:   length (cm) 
      diameter (cm) 
      coiling index (turns/length) 
      direction of cord spiral 
      cord insertion site 
      true knots 
 
Checklist for placental examination:  trimmed weight (g) 
measurements in 3 dimensions (cm) 
present/absence of:  infarct (s), haematoma, 
fibrin, maternal surface thrombus 
         
Standard blocks:    cord x 3 (maternal end, fetal end, central) 
membranes (in same cassette as one cord 
block) 
central parenchymal blocks (full-thickness) x 
3 
peripheral parenchymal block (full-thickness) 
x 1 
maternal surface, 2 sections in 1 block 
any lesional tissue 
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Microscopic examination: 
 
Checklist for reporting cord and membranes: funisitis     
      chorioamnionitis 
maternal vascular disease in any adherent 
decidua 
meconium staining/necrosis 
amnion nodosum 
Checklist for reporting placental parenchyma:chorionic plate 
      inflammation, infection, FTV 
      stem villi 
inflammation, infection, FTV, mesenchymal 
dysplasia, storage disease distal villi 
hypoplasia, chorangiosis, VUE, infection, 
storage disease 
intervillous space 
inflammation, infection, haemorrhage, fibrin 
(massive) 
maternal vessels 
mural fibrin deposition 
atherosis  
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